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 ABSTRACT 
Substance use disorder (SUD) is one of the most common comorbid conditions in adults with 
attention deficit-hyperactivity disorder (ADHD). There are still few studies that address 
combined ADHD and SUD as compared to studies on ADHD without SUD. The aims of the 
present thesis were (1); to conduct a clinical characterization of men with ADHD in 
compulsory care for severe SUD; (2) to investigate whether pharmacological treatment in 
ADHD/SUD cases was associated with improved long-term psychosocial outcomes; (3) to 
explore the feasibility of DBT (dialectic behavior therapy)-based skills training in 
ADHD/SUD patients in compulsory care; and (4) to explore the association between the 
skills training and the psychosocial outcome after six months. All studies were conducted at a 
compulsory care institution for men. 
In the clinical characterization (Study I), 60 men with ADHD and SUD were compared with 
(1) 120 men in compulsory care for severe substance abuse without a known ADHD 
regarding comorbid psychiatric symptoms, psychosocial background, treatment history, and 
cognition, and with (2) 107 men with ADHD but without severe SUD from an outpatient 
psychiatric clinic. In Study II, a comparison was made between 30 patients who had received 
pharmacological treatment for ADHD and 30 non-treated patients. The long-term outcome 
was measured as the current status regarding abuse, voluntary rehabilitation, accommodation 
and employment, as well as mortality. In Study III, the feasibility and acceptability of DBT-
based skills training were explored; 40 patients were included. The patients were follow-up 
six months after discharge from compulsory care, (Study IV). The outcome measures were 
substance abuse status, voluntary treatment status, and accommodation and employment 
status. 
The characteristics of the ADHD/SUD found in Study I were an early onset of antisocial 
behavior that persisted into adulthood and poor cognitive skills. Study II showed that the 
overall mortality was high (8.3%) and that the pharmacologically treated group had 
significantly better outcomes in all measured psychosocial parameters. In Study III, it was 
found that the DBT-based skills training for ADHD was feasible and acceptable in a context 
of compulsory care for SUD. Significant symptom reduction, as well as an increased general 
well-being, was also found. The completers of the DBT-based skills training had fewer 
relapses and were more often in voluntary treatments, compared to non-completers in the six-
month follow-up study (Study IV). However, no causal conclusion regarding the relationship 
  
between the DBT-based skills training and the psychosocial outcome can be drawn due to the 
base-line differences between completers and non-completers, as well as the lack of a control 
group.  
 
To sum up, ADHD in combination with SUD is a particularly disabling condition.  The 
combination of severe substance abuse, poor general cognitive ability, severe psycho-social 
problems, including indications of antisocial behavior, and other co-existing psychiatric 
conditions should be considered in treatment planning for adults with ADHD and SUD. 
Pharmacological treatment of ADHD in individuals with ADHD and severe SUD may 
decrease the risk of relapse and increase the patients’ ability to follow a nonpharmacological 
rehabilitation plan and thereby improve their long-term outcomes. Use of the structured 
treatment setting in the compulsory care for SUD for the initiation and stabilization of the 
pharmacological treatment for ADHD may be beneficial for high-risk populations. 
Furthermore, adapted structured treatments, such as DBT-based skills training, may be 
feasible in compulsory care and useful for some patients in this group. Discontinuation of 
voluntary treatment programs during the compulsory care may indicate low motivation or 
ability to participate in voluntary treatment and therefore predict a negative outcome after 
discharge. 
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1 INTRODUCTION  
Attention deficit-hyperactivity disorder (ADHD) is a neurodevelopment disorder which, in 
most cases, persists into adulthood. In adults, ADHD is associated with considerable 
functional impairments and co-existing psychiatric disorders, including substance use 
disorder (SUD). The aims of the present thesis were to characterize male patients with 
ADHD in compulsory care for SUD in order to explore the long-term outcome of 
pharmacological treatment for ADHD in this patient group, to investigate the feasibility of 
dialectical behavior therapy (DBT)-based skills training in a compulsory care context, and to 
explore the association between the skills training program and psychosocial functioning six 
months after discharge from compulsory care. 
1.1 ADHD 
1.1.1 The Conceptualization and nomenclature of the ADHD   
ADHD-like symptoms were described as mental restlessness and over-activity by physicians 
as far back as the 18th century (Lange, Reichl, Lange, Tucha, & Tucha, 2010). In the 20th 
century, the conceptualization and view of the disorder changed. In terms of a defect in moral 
control, George Still described symptoms similar to today’s definition of ADHD in 1902  (R. 
A. Barkley & Peters, 2012). Later, in the 1930s and 1940s, restlessness and hyperactivity-
impulsivity came to be seen as being caused by an acquired brain damage, reflected in the 
diagnostic term, Minimal Brain Damage. In the 1960s, the diagnosis Minimal Brain 
Dysfunction was introduced, referring to more extensive neurological causes of the disorder 
than brain trauma or infections. Further shifts of the conceptualization are reflected in the 
introduction of the diagnostic term “Hyperkinetic reaction of childhood” in DSM-II in 1967 
and replaced by “Attention deficit-hyperactivity disorder” in 1987 when the third edition of 
DSM was published (American Psychiatric Association, 1980). During recent decades, the 
view concerning the disorder has been influenced by the current knowledge of the persistent 
nature of childhood ADHD with increased opportunities for adults with ADHD to be 
diagnosed and treated (R. A. Barkley, Fischer, Smallish, & Fletcher, 2002). Furthermore, the 
recent extensive increase in knowledge in genetics and neurobiology has contributed to our 
understanding of ADHD (Lange et al., 2010). 
1.1.2 Diagnostic criteria 
The fifth edition of the diagnostic system DSM (American Psychiatric Association, 2013) 
was published in 2013. The symptom criteria for ADHD remains unchanged with the 18 
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symptoms similar to those described  in DSM-IV (American Psychiatric Association, 1994) 
(Table 1), divided into the two domains Inattention and Hyperactivity/impulsivity. The main 
changes in the diagnostic criteria of ADHD in DSM-V (Table 2), compared to DSM-IV, 
include the introduction of a dimensional measure, i.e., a rating of the severity (mild, 
moderate, and severe) of the inattention and hyperactivity symptoms and the accompanying 
impairments. Furthermore, there is a change in the criterion for the onset of the ADHD 
symptoms, from “before seven years” to “before 12 years”. The cut-off limits for symptoms 
required for a diagnosis in adults have been changed from six, which are required for younger 
persons, to five. This applies to both attention and hyperactivity/ impulsivity. In DSM-V, 
each listed symptom is followed by examples of how it may show up in different age groups 
in order to be applicable to both older adolescents and adults. Furthermore, the requirement 
for functional impairments has been moderated, from requiring ADHD-related impairments 
in at least two settings to several ADHD symptoms which must be present in two or more 
settings. An additional change is that a simultaneous presence of ADHD and Autism 
spectrum disorder (ASD) is allowed. However, ADHD will still be ruled out if the symptoms 
only occur during the course of schizophrenia or if other psychotic disorders are not better 
explained by other mental disorder, such as Mood disorder, Anxiety disorder, Dissociative 
disorder or Personality disorder. 
In ICD-10 (World Health Organization, 1992), ADHD is termed Hyperkinetic disorder. In 
essence, the list of ADHD symptoms overlap in the two systems, even though the ICD 
criteria are more restricted than the DSM criteria. To meet the criteria of Hyperkinetic 
disorder, symptoms of both attention (5 symptoms), hyperactivity (3 symptoms) and 
impulsivity (1 symptom) are required, as compared to the requirements in the DSM system: 
six or more symptoms of inattention and/or hyperactivity. Furthermore, the exclusion criteria 
are stricter. If the criteria are met regarding Mood disorder, Anxiety disorder, some type of 
Reactive disorder, Manic state, or Neurological disease, these diagnoses take precedence over 
Hyperkinetic disorder, unless there is evidence of a separate Hyperkinetic disorder. 
Symptoms of Conduct disorder are neither exclusion nor inclusion criteria for Hyperkinetic 
disorder, but represent a diagnostic subgroup, designated as Hyperkinetic conduct disorder. 
Thus, Hyperkinetic disorder is considered to refer to individuals with the most severe ADHD 
symptoms. 
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Table 2. The DSM-5 criteria for ADHD 
(A)  Inattention: Six or more symptoms of inattention for children up to age 16, or 
five or more for adolescents 17 and older and adults; symptoms of inattention 
have been present for at least 6 months, and they are inappropriate for the 
developmental level:  
1) Often fails to give close attention to details or makes careless mistakes in 
schoolwork, at work, or in other activities. 
2) Often has trouble holding attention on tasks or play activities. 
3) Often does not seem to listen when spoken to directly. 
4) Often does not follow through on instructions and fails to finish schoolwork, 
chores, or duties in the workplace (e.g., loses focus, side-tracked). 
5) Often has trouble organizing tasks and activities. 
6) Often avoids, dislikes, or is reluctant to do tasks that require mental effort 
over a long period of time (such as schoolwork or homework). 
7) Often loses things necessary for tasks and activities (e.g., school materials, 
pencils, books, tools, wallets, keys, paperwork, eyeglasses, mobile 
telephones). 
8) Is often easily distracted. 
9) Is often forgetful in daily activities. 
(B)  Hyperactivity and Impulsivity: Six or more symptoms of hyperactivity-
impulsivity for children up to age 16, or five or more for adolescents 17 and older 
and adults; symptoms of hyperactivity-impulsivity have been present for at least 
6 months to an extent that is disruptive and inappropriate for the person’s 
developmental level:  
1) Often fidgets with or taps hands or feet, or squirms in seat. 
2) Often leaves seat in situations when remaining seated is expected. 
3) Often runs about or climbs in situations where it is not appropriate 
(adolescents or adults may be limited to feeling restless). 
4) Often unable to play or take part in leisure activities quietly. 
5) Is often "on the go" acting as if "driven by a motor". 
6) Often talks excessively. 
7) Often blurts out an answer before a question has been completed. 
8) Often has trouble waiting his/her turn. 
9) Often interrupts or intrudes on others (e.g., butts into conversations or games) 
In addition, the following conditions must be met: 
1) Several inattentive or hyperactive-impulsive symptoms were present before 
age 12 years. 
2) Several symptoms are present in two or more settings (e.g., at home, school 
or work; with friends or relatives; in other activities). 
3) There is clear evidence that the symptoms interfere with, or reduce the 
quality of, social, school, or work functioning. 
4) The symptoms do not happen only during the course of schizophrenia or 
another psychotic disorder. The symptoms are not better explained by another 
mental disorder (e.g. Mood disorder, Anxiety disorder, Dissociative disorder, 
or a Personality disorder). 
Based on the types of symptoms, three kinds (presentations) of ADHD can 
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occur: 
Combined Presentation: if enough symptoms of both criteria inattention and 
hyperactivity-impulsivity were present for the past six months 
Predominantly Inattentive Presentation: if enough symptoms of inattention, but not 
hyperactivity-impulsivity, were present for the past six months 
Predominantly Hyperactive-Impulsive Presentation: if enough symptoms of 
hyperactivity-impulsivity, but not inattention, were present for the past six months. 
Because symptoms can change over time, the presentation may change over time as 
well. 
 
 
Table 3. The ICD-10 diagnostic criteria for Hyperkinetic disorder 
 
A. 
At least six  of the following symptoms of Inattention have persisted for at least six 
months to a degree that is maladaptive and inconsistent with developmental levels: 
Inattention  
1) Often fails to give close attention to details or makes careless mistakes in  
    schoolwork, work, or other activities. 
2)  Often has difficulty sustaining attention in tasks or play activities. 
3)  Often does not seem to listen when spoken to directly. 
4)  Often does not follow through on instructions and fails to finish schoolwork, 
     chores, or duties in the workplace (not due to oppositional behavior or failure to  
     understand instructions). 
5)  Often has difficulty organizing tasks and activities. 
6)  Often avoids, dislikes, or is reluctant to engage in tasks that require sustained 
     mental effort (such as schoolwork or homework).  
7)  Often loses things necessary for tasks or activities (e.g., toys, school assignments,  
     pencils, books, or tools). 
8)  Is often easily distracted by extraneous stimuli. 
9)  Is often forgetful in daily activities. 
Six or more of the following symptoms of Hyperactivity-impulsivity have persisted 
for at least six months to a degree that is maladaptive and inconsistent with 
developmental level.   
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Hyperactivity 
1) Often fidgets with hands or feet or squirms in seat. 
2) Often leaves seat in classroom or in other situation in which remaining seated is 
    expected. 
3) Often runs about or climbs excessively in situations in which it is inappropriate (in 
     adolescents or adults, may be limited to subjective feelings of restlessness). 
 
Impulsivity 
1) Often blurts out answers before questions have been completed. 
2) Often has difficulty awaiting turn. 
3) Often interrupts or intrudes on others (e.g., at school or work and at home). 
4) Is often unduly noisy in playing or has difficulty in engaging in leisure activities 
    quietly. 
5) Is often “on the go” or often acts as if “driven by a motor”. 
6) Often talks excessively. 
B. Some hyperactive-impulsive or inattentive symptoms that caused impairment 
were present before age 7 years. 
C. Some impairment from the symptoms is present in two or more settings (e.g., at 
school or work and at home). 
D. There must be clear evidence of clinically significant impairment in social, 
academic, or occupational functioning. 
E. The symptoms do not occur exclusively during the course of a Pervasive 
developmental disorder, Schizophrenia, or other Psychotic disorder and are not better 
accounted for by another Mental disorder (e.g., Mood disorder, Anxiety disorder, 
Dissociative disorder, or a Personality disorder). 
 
 
1.1.3 Prevalence 
Estimations of the prevalence of the ADHD rates vary considerably. One explanation may be 
that estimation of the prevalence may be lower in studies using the ICD-criteria for ADHD, 
which are stricter than the criteria in DSM. The prevalence has also been shown to vary 
depending on which version of DSM has been used in different studies (Faraone, Sergeant, 
Gillberg, & Biederman, 2003). Another explanation may be different methodologies in the 
conducted studies (G. Polanczyk, de Lima, Horta, Biederman, & Rohde, 2007). 
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In individuals up to age 18, the pooled worldwide prevalence has been estimated to be 5.29% 
(G. Polanczyk et al., 2007). According to a later systematic review and meta-regression 
analysis, there is no evidence of an increased number of children meeting the criteria for 
ADHD during the past three decades (G. V. Polanczyk, Willcutt, Salum, Kieling, & Rohde, 
2014). However, the extension of the age-of-onset criterion from seven to 12 years in DSM-V 
has been shown to lead to an increase in the prevalence rate in US children and adolescents 
from 7.38% to 10.84% (based on parent reports) (Vande Voort, He, Jameson, & Merikangas, 
2014). Furthermore, data from the National Survey of Children’s Health (NSCH) have shown 
that ever-diagnosed ADHD increased in children/adolescents (age 4–17 years) from 7.8% in 
2003 to 11% in 2011, signifying an increase of 22% from 2003 to 2007, and 16% from 2007 
to 2011. Current ADHD increased from 7.2% in 2007 to 8.8% in 2011 (Visser et al., 2014). 
In a meta-analysis including studies  on children, adolescents, and adults (Willcutt, 2012), the 
prevalence ranged between 5.0% and 7.1%. In adults, Fayyad found in a cross-national study 
that the estimated prevalence of adult ADHD ranged between 1.2% and 7.3% (Fayyad et al., 
2007).  
1.1.4 Genetics 
Family, twin, adoption, and other behavior genetic studies have shown a considerable 
heritability in ADHD (Z. Chang, Lichtenstein, Asherson, & Larsson, 2013; Faraone et al., 
2005; Nikolas & Burt, 2010; Thapar, Holmes, Poulton, & Harrington, 1999). The mean rate 
of heritability has been estimated to be 76% (Faraone et al., 2005), ranging from 60% to 90%. 
Although the high heritability has been established, trials for identifying specific risk genes 
involved in ADHD have not led to firm conclusions. Regarding the immense amount of DNA 
variants, it has not been  possible to say so far which of them are truly associated with ADHD 
(Faraone, 2014). However, genes involved in the dopaminergic pathway, particularly the 
dopamine D4 (DRD4) and dopamine D5 (DRD5) genes, are thought to be associated with 
ADHD (Coghill & Banaschewski, 2009; Gizer, Ficks, & Waldman, 2009; Wu, Xiao, Sun, 
Zou, & Zhu, 2012). The common view is that a plurality of genes are involved (Frodl, 2010), 
each one contributing with a small, but significant, effect (Neale et al., 2010). Moreover, 
common genetic variants, as well as neurocognitive traits and behavioral dimensions related 
to ADHD, have been found in the general population (Faraone, 2014; Martin, Hamshere, 
Stergiakouli, O'Donovan, & Thapar, 2015). All these findings indicate a complex genetic 
architecture in ADHD, suggesting a dimensional ADHD model, and also implying that 
clinically defined ADHD may be seen as an extreme of a continuous trait (Groen-Blokhuis et 
al., 2014; H. Larsson, Anckarsater, Rastam, Chang, & Lichtenstein, 2012).  
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An additional research approach is the gene-by-environment interaction, proposing that 
environmental factors may contribute to the manifestation of genetic effects (Coghill & 
Banaschewski, 2009; Cortese et al., 2012; J. Nigg, Nikolas, & Burt, 2010; Thapar, Langley, 
Asherson, & Gill, 2007), explained as a genetic sensitivity to a particular environmental 
factor (Pennington, 2009).  
Among the possible environmental factors contributing to ADHD, it has been found that 
prenatal exposure to alcohol and drugs, complications during pregnancy, premature birth, and 
a low birth weight are associated with the condition (Banerjee, Middleton, & Faraone, 2007; 
Botting, Powls, Cooke, & Marlow, 1997; Langley, Holmans, van den Bree, & Thapar, 2007; 
Milberger, Biederman, Faraone, Guite, & Tsuang, 1997). 
Several studies suggest a possible causality regarding maternal smoking during pregnancy as 
an environmental factor for ADHD offspring (Banerjee et al., 2007; Langley, Rice, van den 
Bree, & Thapar, 2005; Rodriguez & Bohlin, 2005), while the conclusion from a later study is 
that the association between maternal smoking during pregnancy and offspring ADHD may 
be explained by unmeasured confounding (Skoglund, Chen, D'Onofrio, Lichtenstein, & 
Larsson, 2014). In a meta-analysis, Wood et al. (2009) have estimated the average 
contribution of shared environment factor in ADHD to be 24.8% (Wood, Buitelaar, Rijsdijk, 
Asherson, & Kuntsi, 2010). 
1.1.5 Neurobiology of ADHD 
Neuroanatomically, a reduced brain volume has been found in individuals with ADHD, both 
globally and in specific regions, and both regarding gray and white matter (Castellanos & 
Acosta, 2004; Nakao, Radua, Rubia, & Mataix-Cols, 2011; Seidman et al., 2011). According 
to meta-analyses, the most consistent finding is a volume reduction in the basal ganglia 
(Castellanos & Acosta, 2004; Frodl & Skokauskas, 2012), prefrontal cortex, and cerebellum 
(Seidman et al., 2006; P. Shaw & Rabin, 2009). A reduction of cortical thickness over large 
areas has also been found (Luders et al., 2009; Narr et al., 2009; P. Shaw & Rabin, 2009).  
The association between ADHD and a dysregulated dopamine activity in the brain reward 
centers, via the five  receptors D1-D5 (Wu et al., 2012), is well established. Dopamine also 
plays a role in drug abuse and addiction (Volkow, Fowler, Wang, & Swanson, 2004), which 
may explain the association between ADHD and SUD (Carpentier et al., 2013). An 
interaction between dopamine and the neurotransmitters, serotonin, GABA, and 
norepinephrine, in ADHD has also been suggested (Blum et al., 2008; Groenman et al., 
2015). Furthermore, ADHD has been suggested to be associated with inadequate activity of 
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acetylcholine (Wallis et al., 2009), endocannabinoids (van Hell et al., 2012), and glutamate 
(Dimatelis et al., 2015).  
Furthermore, a functional disconnectivity between different brain regions has been found in 
MRI studies (Cortese & Castellanos, 2012; Dickstein, Bannon, Castellanos, & Milham, 2006; 
Konrad et al., 2010). Impaired connectivity has been found particularly in the default mode 
network (DMN), both in the network itself and in its connection to the cognitive control 
network. The dysfunction refers to failures in deactivating the DMN (activated at wakeful 
rest) at demands on goal-directed tasks, including sustained attention. The cognitive control 
network is associated with the functions working memory, inhibitory control, and set shifting, 
and the dysfunctional connectivity between the DMN and the cognitive control network also 
contributes to the impairments in sustaining attention (Posner, Park, & Wang, 2014).  
Furthermore, impaired connectivity is also found in the neural circuits, which are suggested 
to be associated with the affective and motivational systems [within the cortio-striato-
thalamo-cortical (CSTC)] loops (Castellanos, Kelly, & Milham, 2009; Konrad et al., 2010). 
Thus, impaired functional connectivity is implicated in both the attentional and the affective 
and motivational system (Posner et al., 2014; Sonuga-Barke, Sergeant, Nigg, & Willcutt, 
2008).  
1.1.6 ADHD and Cognition 
1.1.6.1 General cognitive ability in ADHD 
On average, adults with ADHD as a group have been shown to have a slightly lower general 
intellectual ability than healthy controls (Frazier, Demaree, & Youngstrom, 2004; Schoechlin 
& Engel, 2005). Bridgett and Walker (2006) found lower average IQ scores of 2.94 in the 
ADHD group compared to controls (Bridgett & Walker, 2006). Comorbid psychiatric 
disorders in adult ADHD have been found to entail more cognitive difficulties than adult 
ADHD without additional psychiatric disorders (Theiling & Petermann, 2014). Furthermore, 
ADHD, in combination with specific learning disabilities in arithmetic and reading/spelling, 
has been found to be associated with lower IQ scores than solely ADHD (Frazier et al., 2004; 
Seidman, Biederman, Monuteaux, Doyle, & Faraone, 2001).  
Considerable impairments in multiple cognitive domains are found in ADHD individuals 
compared to healthy controls (Fuermaier et al., 2015; Hervey, Epstein, & Curry, 2004). 
However, no psychometric cognitive test or test profile allows individual diagnoses of 
ADHD since individuals with ADHD display unique profiles of neuropsychological 
functioning (Lange et al., 2014). Moreover, IQ scores cannot explain the lower academic 
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performance and functional impairments associated with ADHD. Arnold et al. found that the 
difference in academic achievements between individuals with untreated ADHD and controls 
remained after controlling for IQ (Arnold, Hodgkins, Kahle, Madhoo, & Kewley, 2015). 
Furthermore, a high IQ may be associated with cognitive difficulties and low achievements 
due to executive dysfunctions (Antshel et al., 2010; Kaplan, Crawford, Dewey, & Fisher, 
2000). 
The most widely used intelligence measure in adulthood is the Wechsler Adult Intelligence 
Scale (WAIS). In versions prior to the current WAIS, the WAIS-IV (Wechsler, 2008), the 
working memory and processing speed subtests were included in the full-scale intelligence 
quotient (FSIQ), meaning that the specific impairments in ADHD were included in the 
calculation of the global intellectual capacity. In WAIS IV, the latest version of the test 
instrument, an alternative index to FSIQ has been introduced (General Ability Index; GAI). 
GAI aims to reduce the influence of the executive functions working memory and processing 
speed. A significant difference between FSIQ and GAI has also been found in ADHD adults, 
but not in matched controls  (Theiling & Petermann, 2014). 
1.1.6.2 Executive dysfunctions in ADHD 
Barkley (1997) has defined Executive functions (EFs) as neurocognitive processes 
responsible for goal-directed behaviors and deficient self-control. The definition implies 
deficits in response inhibition as the core characteristic in ADHD, affecting all other EF 
processes (R. A. Barkley, 1997a, 1997b). This model has later been supplemented by a more 
multidimensional view of the executive dysfunctions in ADHD. Deficits in impulse 
inhibition, according to Barkley’s model, are, in later models, considered to be just one 
pathway associated with ADHD.  
 
A more elaborated model is the Dual pathway model (Sonuga-Barke, 2003), which refers to 
two separate mechanisms within two domains of functioning. The pathway of inhibitory 
cognitive control (R. A. Barkley, 1997a) refers  to an inability to pursue top-down control, 
i.e., to overcome stimulus triggers and/or affect arousal in favor of pursuing behavior, in 
order to achieve more long-term goals. The other pathway refers to a neurally based 
motivational dysfunction, including an aversion of delayed and future rewards (Sonuga-
Barke, 2002; Sonuga-Barke et al., 2008). The motivational system is less associated with 
cognition and academic achievement and more with affective state (Castellanos, Sonuga-
Barke, Milham, & Tannock, 2006). The terms “hot” and “cold” EF are associated with these 
different pathways. Inattention in ADHD (Castellanos et al., 2006) and the cognitive 
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functions, Inhibition, Vigilance, Spatial working memory, and some measures of Planning 
have been suggested to be related to “cold” EF and a dysfunctional cognitive control system  
(Willcutt, Doyle, Nigg, Faraone, & Pennington, 2005). Hyperactivity/ impulsivity is, in this 
model, suggested to be associated with “hot” EF. However, although being the substantial 
role of executive dysfunctions in ADHD, not all diagnosed with ADHD have disabling 
executive dysfunctions (Castellanos et al., 2006; J. T. Nigg et al., 2005; B. A. Roberts, 
Martel, & Nigg, 2013).  
1.1.6.3 Functional impairments 
In practically all domains of life, and regardless of age, ADHD is associated with 
considerable functional impairments. Educational problems and academic underachievement 
have been shown to be more common in children with ADHD than in peers without ADHD 
(Biederman, Petty, et al., 2008). The functional impairments in children and adolescents may 
contribute to an increased risk of an antisocial trajectory and substance abuse (Gordon, Tulak, 
& Troncale, 2004; Sullivan & Rudnik-Levin, 2001; van Emmerik-van Oortmerssen et al., 
2012).   
Adults with ADHD have more occupational impairments, including lower levels of 
professional employment, poorer work performance, and higher rates of quitting or being 
fired (R. A. Barkley, & Murphy, K. R., 2010; Biederman J, 2006; Fletcher, 2014). Compared 
to controls, ADHD in adults is also associated with higher rates of divorce and less 
satisfaction with  family, social, and professional lives, compared to controls (Biederman J, 
2006).  
1.1.7 Coexisting psychiatric disorders 
ADHD is associated with a wide range of co-existing psychiatric disorders (Biederman, 
Newcorn, & Sprich, 1991; Torgersen, Gjervan, & Rasmussen, 2006; Yoshimasu et al., 2012). 
The rates of estimated comorbidity over the life span vary between 65% and 89% (Sobanski 
et al., 2007; Sobanski et al., 2008). 
In children and adolescents, Oppositional defiant disorder (ODD) and Conduct disorder (CD) 
are the most common co-existing disorders in ADHD (Biederman et al., 1991). Anxiety and 
Mood disorders are also frequently reported (Masi, Millepiedi, et al., 2003), often in 
combination with ODD and CD (Bendiksen et al., 2014; Frick & Nigg, 2012; Ghosh & 
Sinha, 2012; Kessler et al., 2011).  
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Mood disorders and SUD are the most common co-existing psychiatric conditions in adult 
ADHD, followed by Anxiety disorders (Busch et al., 2002; Faraone, Biederman, & Wozniak, 
2012; Fayyad et al., 2007; Klassen, Katzman, & Chokka, 2010; Masi, Toni, et al., 2003; T. E. 
Wilens et al., 2009). The most frequently reported co-existing personality disorders are 
Borderline personality disorder and Antisocial personality disorder (Anckarsater et al., 2006; 
Matthies et al., 2011; Moffitt, 1990; Philipsen et al., 2009). 
 
1.1.8 Mortality and related risk behaviors in ADHD 
Mortality has been shown to be increased in ADHD. In a large sample of 1.92 million 
individuals in Denmark, the mortality rate per 10,000 per year was 5.85 (4.25 in adults) in 
individuals with ADHD, compared to 2.21 in non-ADHD persons. Thus, during the follow-
up period of 32 years, the risk of a premature death was more than two times higher in 
individuals with ADHD than in those without ADHD (Dalsgaard, Ostergaard, Leckman, 
Mortensen, & Pedersen, 2015). Comorbidity with ODD, CD, and SUD increased the 
Mortality rate ratios (MRRs), but, also without these comorbid disorders, the MMR was 
substantially higher in ADHD individuals.  
Drug abuse per se, especially abuse of illicit drugs, is also related to a high mortality 
(Stenbacka, Leifman, & Romelsjo, 2010). In deceased drug addicts, death has been found to 
be caused by the drug abuse in about in 47% according to toxicological analyses (Jönsson, 
Holmgren, Druid, & Ahlner, 2007).  
Dalsgaard et al. found that, in individuals with ADHD, the causes of death were mainly 
unnatural and mostly associated with accidents (Dalsgaard et al., 2015). In adult ADHD, 
traffic accidents are more common, as compared to the population as a whole (R. A. Barkley 
& Cox, 2007; Z. Chang, Lichtenstein, D'Onofrio, Sjolander, & Larsson, 2014). Risk-taking 
behavior, associated with impulsivity, is an independent predictor of driving offences in 
ADHD (Kaye et al., 2014). 
 
1.2 ADHD AND SUBSTANCE USE DISORDER 
1.2.1 Diagnostic criteria of substance use disorder  
For the diagnosis SUD, according to DSM-5 (American Psychiatric Association, 2013), at 
least two of 11 criteria are required to be met, which are clustered in four groups:  
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1.  Impaired control: (1) taking more or for longer than intended, (2) unsuccessful efforts 
to stop or cut down use, (3) spending a great deal of time obtaining, using, or 
recovering from use, (4) craving for substance. 
2. Social impairment: (5) failure to fulfill major obligations due to use, (6) continued use 
despite problems caused or exacerbated by use, (7) important activities given up or 
reduced because of substance use.  
3. Risky use: (8) recurrent use in hazardous situations, (9) continued use despite physical 
or psychological problems that are caused or exacerbated by substance use. 
4. Pharmacologic dependence: (10) tolerance to effects of the substance, (11) 
withdrawal symptoms when not using or using less. However, persons who are 
prescribed medications such as opioids may exhibit these two criteria, but would not 
necessarily be considered to have a Substance use disorder. 
DSM-5 suggests using the number of criteria met as a general measure of severity, from mild 
(2–3 criteria) to moderate (4–5 criteria) and severe (6 or more criteria).  
Finally, new to DSM-5 are cannabis and caffeine withdrawal, and the criteria for Tobacco use 
disorder are now the same as for all other Substance use disorders. 
1.2.2 Prevalence of ADHD in SUD 
The prevalence of ADHD in the general population is estimated to be 1.2%–7.3% (Fayyad et 
al., 2007), as compared with 20%–50% in individuals with SUD, thereby entailing a pooled 
rate of 23.3% (van Emmerik-van Oortmerssen et al., 2012). The extensive variations in the 
estimations of ADHD in SUD have been suggested to be related to several factors such as 
different psychoactive substances involved in the studies, different diagnostic instruments, 
demographic and country-specific factors, treatment/assessment settings, and clinical biases 
(Perez de Los Cobos et al., 2011; van de Glind et al., 2014).  Conversely, the prevalence of 
SUD in adults with ADHD has been estimated to be about 50% (Sullivan & Rudnik-Levin, 
2001). Thus, ADHD is considered to be a strong predictor of SUD (Sullivan & Rudnik-
Levin, 2001; T. E. Wilens, 2011; T. E. Wilens, Biederman, Mick, Faraone, & Spencer, 1997).  
1.2.3 Associations between ADHD and SUD 
As mentioned above, the association between ADHD and all forms of addiction is well 
established (Biederman et al., 1995; Milberger, Biederman, Faraone, Wilens, & Chu, 1997; 
T. E. Wilens, 2004a, 2004b; T. E. Wilens & Fusillo, 2007; T. E. Wilens et al., 2011). The 
ADHD and SUD relationship has been explored from different perspectives, such as 
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biological vulnerabilities, overlapping neurocognitive underpinnings, personality traits, 
additional psychiatric comorbidity, and psychosocial impairments.  
There is a strong indication of a shared genetic basis for SUD and ADHD (Capusan, 
Bendtsen, Marteinsdottir, Kuja-Halkola, & Larsson, 2015; Groman, James, & Jentsch, 2009; 
Skoglund, Chen, Franck, Lichtenstein, & Larsson, 2015; T. E. Wilens, 2004a). The high 
prevalence of ADHD in families with SUD and vice versa indicates a shared familiarity of 
the two disorders (Biederman, Petty, Wilens, et al., 2008; T. E. Wilens, 2004a). It has been 
proposed that specific genotypes increase the risk of ADHD only, while others entail an 
increased risk for the combination of ADHD and SUD (Carpentier et al., 2013). The 
dysregulation of primarily dopamine, as well as serotonin, in both ADHD and SUD has been 
established in several studies (Cardinal, Winstanley, Robbins, & Everitt, 2004; Eagle et al., 
2009; Silva et al., 2014; Szobot, Shih, et al., 2008; Volkow et al., 2004; Volkow et al., 2007).  
Early occurrence of ADHD symptoms and ADHD-related behavior, such as impulsivity and 
lack of self-control (Caspi, Moffitt, Newman, & Silva, 1996; Moffitt et al., 2011; Molina & 
Pelham, 2003), as well as the severity of the ADHD symptoms (Thompson, Riggs, Mikulich, 
& Crowley, 1996), has been found to be associated with adult substance dependence. The 
association between ADHD subtypes and the development and severity of SUD has been 
explored in several studies. One suggestion is that the predominantly inattentive subtype 
(ADHD-I) predicts multiple substance use outcomes (Molina & Pelham, 2003). The 
hyperactivity/impulsivity subtype of ADHD (ADHD-HI) has been found to be independently 
associated with the risk of developing substance abuse (De Alwis, Lynskey, Reiersen, & 
Agrawal, 2014; Elkins, McGue, & Iacono, 2007; Nogueira et al., 2014; Storebö, 2013; Tamm 
et al., 2013). Furthermore, ADHD-HI has been shown to be strongly associated with early 
onset of substance abuse (Z. Chang, Lichtenstein, & Larsson, 2012).  
SUD is, independently of ADHD, associated with an increased rate of additional co-existing 
disorders, including mood, anxiety, psychotic and personality disorders (Fridell, Hesse, & 
Johnson, 2006; Mariani & Levin, 2007; Regier et al., 1990), but higher rates of comorbid 
conditions have been found when ADHD and SUD co-exist (van Emmerik-van Oortmerssen 
et al., 2014; T. E. Wilens, Kwon, et al., 2005). The International ADHD in Substance Use 
Disorder Prevalence (IASP) Study found that 75% of treatment-seeking SUD patients with 
comorbid ADHD had at least one additional comorbid disorder, compared to 37% in SUD 
patients without ADHD. The study also showed different comorbid patterns in the ADHD 
subtypes. On comparing the subtypes (ADHD-C, ADHD-HI, and ADHD-I), major 
depression was more common in the inattentive and combined subtype; hypomania and 
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antisocial personality disorder were more common in the hyperactive/ impulsive and 
combined subtypes. Borderline personality disorder was increased in all three subgroups, 
compared to patients with SUD without ADHD (van Emmerik-van Oortmerssen, van de 
Glind, et al., 2013).  
Based on personality traits, Tarter et al. have proposed two pathways linking childhood 
hyperactivity to SUD in young adulthood. In the so-called internalizing pathway, the 
personality trait neuroticism is suggested to lead to low self-esteem, in turn leading to social 
withdrawal, and to an increased risk for SUD. The other suggested pathway, the externalizing 
one, describes a development from hyperactivity in childhood associated with externalizing 
behaviour, and later to SUD (Tarter, Kirisci, Feske, & Vanyukov, 2007). Among personality 
traits, impulsive anger in childhood is found to be strongly associated with ADHD and a 
predictor of SUD (T. E. Wilens et al., 2011). Additional common intermediate factors 
involving ADHD and SUD are difficulties and shortcomings in different areas of life, such as 
academic and vocational problems, heterogeneous social difficulties, and lack of adequate 
coping skills (Molina & Pelham, 2014). Thus, stress in everyday life, related to the ADHD 
impairments (Hirvikoski, Lindholm, Nordenstrom, Nordstrom, & Lajic, 2009), may be a 
pathway to SUD. From in-depth interviews conducted on both ADHD and ASD patients, 
Kronenberg et al. found that stress was a common reason for starting to use alcohol and drugs 
(Kronenberg, Slager-Visscher, Goossens, van den Brink, & van Achterberg, 2014). 
Furthermore, the continued use of alcohol and drugs may be regarded as an expression of the 
palliative, avoidant, and passive coping styles for coping with stress, which is found to be 
frequent in patients with ADHD (Kronenberg, Goossens, van Busschbach, van Achterberg, & 
van den Brink, 2015). Substance abuse for reduction of stress related to ADHD symptoms 
and to comorbid conditions is related to the self-medication hypothesis (Young & Sedgwick, 
2015). A yearning for belongingness has also been identified as an important driving force 
underlying substance abuse in individuals with ADHD (Nehlin, Nyberg, & Öster, 2015). 
.  
1.2.4 Impulsivity and conduct disorder in ADHD/SUD 
Impulsivity and conduct disorder in childhood hold strong positions as explanatory factors in 
the association between ADHD and SUD.  
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1.2.4.1 Impulsivity 
Impulsivity is a core symptom of ADHD and a precursor to SUD (Crunelle, Veltman, van 
Emmerik-van Oortmerssen, Booij, & van den Brink, 2013; De Alwis et al., 2014; Murphy, 
Barkley, & Bush, 2002). The construct of impulsivity is multifaceted (W. Roberts, Peters, 
Adams, Lynam, & Milich, 2014) and ambiguous in terms of the cognitive, emotional, and 
neural processes that underpin the manifest behaviour. Two paradigms of impulsivity related 
to the dual pathway model are impulsive action and impulsive choice. These two 
manifestations of impulsivity are differently defined, operationalized, and measured. 
Impulsive action refers to an inability to inhibit an automatic motor control (top-down model) 
(R. A. Barkley, 1997b) and impulsive choice refers to an aversion to delayed rewards, 
implying choosing of small immediate rewards instead of delayed greater rewards (bottom-up 
model). The paradigm of delay aversion also suggests that ADHD-related behavior (such as 
activity, frustration/stress and inattention) increases when an immediate reward is not 
available or when expected rewards are absent (Sonuga-Barke et al., 2008). Impulsive action 
and impulsive choice are measured with different neuropsychological tests (stop-signal tasks 
and choice- delayed tasks, respectively), and it has been found that the outcomes of these 
tests are largely uncorrelated (Broos et al., 2012). These findings highlight the heterogeneity 
of both impulsivity and the ADHD disorder. Both delay aversion and inhibitory failure are 
implicated in ADHD (M. V. Solanto et al., 2001) and both models of impulsivity are 
involved in addiction vulnerability (Molina & Pelham, 2014). That is, the impaired higher-
order cognitive control system in ADHD does not inhibit automatic impulses to seek the 
instant gratification/reward that substance use can provide. However, findings also indicate 
that impulsivity is a specific trait in SUD, not specifically mediated by ADHD (Ivanov, 
Schulz, London, & Newcorn, 2008; J. T. Nigg et al., 2006) 
 
1.2.4.2. Conduct disorder 
The substantial role of childhood onset conduct disorder (CD) in the association between 
ADHD and SUD is well established (August et al., 2006; Elkins et al., 2007; Flory & Lynam, 
2003; Harty, Ivanov, Newcorn, & Halperin, 2011; Nogueira et al., 2014; Ohannessian & 
Hesselbrock, 1995; Torok, Darke, & Kaye, 2012; Tuithof, ten Have, van den Brink, 
Vollebergh, & de Graaf, 2012). The ADHD-SUD relationship has even been shown to 
significantly decrease on controlling for the impact of CD. (August et al., 2006; Flory, 
Milich, Lynam, Leukefeld, & Clayton, 2003), indicating that CD during childhood and/or 
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antisocial behavior in adulthood are robust predictors of SUD, independently of ADHD 
(Couwenbergh et al., 2006; Hopfer et al., 2013; King, Iacono, & McGue, 2004; Rodgers et 
al., 2014; Saban et al., 2014; Westermeyer, Thuras, & Carlson, 2005; Wilson & Levin, 2005). 
It has been suggested (Anney et al., 2008; Christiansen et al., 2008) that ADHD/CD 
represents an own etiological entity, only partly overlapping with ADHD as such. This 
proposed subtype represents a more severe disorder than merely ADHD. The diagnosis 
hyperkinetic CD in ICD-10 is in line with this suggested distinct subgroup (Faraone, 
Biederman, Jetton, & Tsuang, 1997; Faraone, Biederman, Mennin, Russell, & Tsuang, 1998). 
 
1.3 TREATMENT OF ADHD 
1.3.1 Pharmacological treatment of ADHD 
The short-term effect of psychostimulants on symptom reduction in ADHD is well 
established (Bitter, Angyalosi, & Czobor, 2012; Castells, Cunill, & Capella, 2013; Faraone & 
Glatt, 2010; Faraone, Spencer, Aleardi, Pagano, & Biederman, 2004; Koesters, Becker, 
Kilian, Fegert, & Weinmann, 2009; Meszaros et al., 2009). Long-term effects of 
pharmacological treatment have also been found in several studies (Adler, Spencer, Milton, 
Moore, & Michelson, 2005; Buitelaar et al., 2012; Fredriksen, Halmoy, Faraone, & Haavik, 
2012), although much less prominently. 
In current guidelines for the treatment of ADHD (Bolea-Alamanac et al., 2014; CAADRA, 
2011; S. J. Kooij et al., 2010; National Board of Health, 2014a; National Institute for Clinical 
Excellence, 2008), psychostimulants are recommended as the first choice of treatment of 
ADHD.  
1.3.1.1 Unresponsiveness and adverse effects of stimulant medication 
About 20%–50% of ADHD individuals continue to have residual symptoms or find the 
adverse effects of stimulant medication intolerable (Wender, 1998; T. E. Wilens, Spencer, & 
Biederman, 2002). Reported adverse effects are increases in systolic and diastolic blood 
pressure and heart rate, insomnia, dysphoria, tics, obsessiveness, headaches, edginess, loss of 
appetite, and loss of weight (Kolar et al., 2008; T. Wilens, Spencer, TJ., Biederman, J., et.al., 
2001; T. E. Wilens et al., 2002). Serious adverse effects are, however, uncommon (Graham, 
2008) 
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1.3.1.2 Risks of psycho-stimulant medication 
The risks of treatment with stimulants, associated with the abuse potential, are misuse of 
prescribed stimulants, side-abuse, and diversion (Bukstein, 2008; Faraone & Wilens, 2007; 
Klassen, Bilkey, Katzman, & Chokka, 2012; Kollins, 2008; Mariani & Levin, 2007; Perez de 
Los Cobos, Sinol, Perez, & Trujols, 2012; Sepulveda et al., 2011). Comorbid disorders such 
as CD/ASPD and bipolar disorder and SUD have been regarded as risk factors (Kollins, 
2008). 
 
A question has been raised as to whether there is an increased risk of stimulant medication in 
childhood increasing the risk of developing SUD in adolescents or adults (sensitization 
hypothesis) (Robinson & Berridge, 1993; Strakowski & Sax, 1998). The current evidence 
does not, however, support an association between pharmacological treatment of ADHD and 
a later increased risk of SUD (R. A. Barkley, Fischer, Smallish, & Fletcher, 2003; 
Biederman, Monuteaux, et al., 2008; Z. Chang, Lichtenstein, P., Halldner, L., D'Onofrio, B. 
M., Serlachhius, E., Fazel, S., Långström, N., Larsson, H., 2013; Groenman et al., 2013; 
Mannuzza et al., 2008). On the contrary, stimulant medication may lower the risk of 
developing SUD and substance abuse (Z. Chang, Lichtenstein, P., Halldner, L., D'Onofrio, B. 
M., Serlachhius, E., Fazel, S., Långström, N., Larsson, H., 2013; Groenman et al., 2013).  
 
1.3.2 Pharmacological treatment of combined ADHD and SUD 
The findings in efficacy studies on pharmacological treatment of ADHD in patients with 
comorbid SUD are less conclusive compared to the findings in studies on pharmacological 
treatment of ADHD patients without SUD (Castells et al., 2011; Cunill, Castells, Tobias, & 
Capella, 2014; T. E. Wilens, Monuteaux, et al., 2005). In several studies, methylphenidate 
treatment has been shown to reduce ADHD symptoms in patients with comorbid SUD, while 
the benefits with regard to SUD have been more uncertain (Castaneda, Levy, Hardy, & 
Trujillo, 2000; Klassen et al., 2012; Schubiner et al., 2002; Somoza et al., 2004). However, in 
patients with combined ADHD and SUD in a forensic context, short- term efficacy of 
stimulant medication has been confirmed (Ginsberg & Lindefors, 2012), as well as long-term 
improvements in cognitive functions, quality of life, and psychosocial functioning (Ginsberg, 
Hirvikoski, Grann, & Lindefors, 2012; Konstenius et al., 2013). Otherwise, the recommended 
treatment of first choice in patients with ADHD and SUD is non-stimulants (Bolea-Alamanac 
et al., 2014; S. J. Kooij et al., 2010; National Institute for Clinical Excellence, 2008).  
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The question has been raised as to whether the unsure outcome of stimulant treatment for 
ADHD with comorbid SUD may depend on inadequate dosage (Levin et al., 2015). With 
reference to imaging studies indicating a greater underlying dysregulation of dopamine 
transmission and an increased tolerance to stimulants in ADHD/SUD individuals (Volkow, 
Fowler, & Wang, 1999; Volkow et al., 2004), two RCT studies have been conducted in 
which more robust doses have been administered using  individualized treatment protocols 
comprising up to 180 mg/day of methylphenidate (Konstenius et al., 2013) and treatment 
with extended-release mixed amphetamine salts (60 or 80 mg) in combination with cognitive 
behavior therapy in patients with cocaine use disorder (Levin et al., 2015). Both studies found 
symptom reduction and a decreased risk of relapses. 
 
1.3.2.1 Recommendations of pharmacological treatment in patients with ADHD and 
SUD 
In current guidelines for the treatment of combined ADHD and SUD (Bolea-Alamanac et al., 
2014; S. J. Kooij et al., 2010; National Institute for Clinical Excellence, 2008), non-stimulant 
medication is recommended as the first-line treatment. There are also recommendations for 
individualized clinical decisions based on a careful analysis of the advantages and 
disadvantages of pharmacological treatment (Perez de Los Cobos et al., 2012). If stimulant 
medication is found to be applicable, a long-acting formulation such as OROS® 
methylphenidate is recommended since short-acting stimulants provide a more direct 
stimulant effect (Kollins, 2008; Schubiner, 2005; Szobot, Rohde, et al., 2008). 
  
Additional recommended treatment strategies for patients with combined ADHD and SUD 
are interventions plans, psycho-education, frequent visits to the treating clinic, keeping track 
of pills (in outpatients), monitoring by administering the medication under close supervision, 
urine toxicology screening, treatment response with rating scales, and psychosocial 
interventions such as cognitive behavioral therapy, relapse prevention, and motivational 
interviewing (Bukstein, 2008; Kollins, 2008; Mariani & Levin, 2007; Upadhyaya, 2007). The 
National Board of Health and Welfare in Sweden recommends that ADHD should be treated 
in parallel with treatment of the substance abuse and, furthermore, that the clinical 
assessment, as well as prescription of the ADHD medication and the follow-up of the 
treatment, should be handled by a clinician experienced in SUD. Finally, the recommendation 
is that the health care providers and social services collaborate  in the treatment of this patient 
group (National Board of Health, 2014a). 
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1.3.3 Psychological treatment of ADHD 
As previously mentioned, about 20%–50% of ADHD patients are deemed to be non-
responders to pharmacological treatment for ADHD. Insufficient symptom reduction and/or 
adverse effects are common causes of discontinuation of the medication (Bejerot, Ryden, & 
Arlinde, 2010; Gualtieri, Ondrusek, & Finley, 1985; Mattes, Boswell, & Oliver, 1984; 
Wender, 1998; T. E. Wilens et al., 2002). A study has shown that after eight years, only 
32.5%  had medicated at least 50% of the days of the previouys year and, after 16 years, only 
10.0% were on medication (Molina et al., 2009). Thus, for patients who choose not to 
medicate for ADHD and for medicated patients who have residuals ADHD symptoms and 
functional impairments, alternatively and/or complementary psychological treatments may be 
needed to provide strategies and skills for coping with the accompanying functional 
impairments in ADHD. 
 
In 1999 Wiggins introduced a brief group treatment for ADHD targeting specific 
organizational problems (Wiggins, 1999). The results suggested that the psycho-educational 
model had a beneficial effect on disorganization, inattention, and emotional lability. 
However, this study demonstrated a negative effect on the participants’ self-esteem, which 
was suggested to be caused by increased awareness of their difficulties in everyday life. Later 
studies on psychoeducational interventions for adults with ADHD have shown promising 
results (Hirvikoski, Waaler, Lindstrom, Bolte, & Jokinen, 2014; Montoya, Colom, & Ferrin, 
2011; Vidal et al., 2013).  
 
During the last ten years, there has been a growing number of studies on CBT-based 
treatment programs for ADHD. Promising results have been shown in individual therapies 
(Safren et al., 2010; C. S. Stevenson, Stevenson, R. J., & Whitmont, S. , 2003; C. S. 
Stevenson, Whitmont, S., Bornholt, L., Livesey, D., Stevenson, R.J., 2002), as well as in 
group therapies (Emilsson et al., 2011; M. V. Solanto, Marks, D. J., Wasserstein, J., Mitchell, 
K., Abikoff, H., Alvir, J. M. J., Kofman, M. D., 2010; C. S. Stevenson, Whitmont, S., 
Bornholt, L., Livesey, D., Stevenson, R.J., 2002; Weiss et al., 2012; Young et al., 2015; 
Zylowska et al., 2008). Dialectical behavior-based therapy for ADHD (B. Hesslinger, 
Philipsen, A., Richter, H., 2004; B. Hesslinger et al., 2002; Philipsen et al., 2007) has been 
developed in Germany and evaluated in psychiatric outpatient contexts. The results have 
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shown that the DBT-based treatment may be feasible and acceptable and lead to significant 
symptom reduction in psychiatric outpatient contexts (Hirvikoski et al., 2011; Philipsen et al., 
2007).  
On comparing the treatment modalities, pharmacological, nonpharmacological, and 
combined treatment, the latter has been shown in a systematic review to be associated with 
the greatest long-term functional improvement, both in terms of the proportion of improved 
outcomes and effect size (Arnold, Hodgkins, Caci, Kahle, & Young, 2015). 
Recommendations for multimodal treatment of ADHD have also been included increasingly 
in different national and/or official guidelines during recent years (Bolea-Alamanac et al., 
2014; S. J. Kooij et al., 2010; National Board of Health, 2014a; National Institute for Clinical 
Excellence, 2008). There is still, however, too great a lack of meta-analyses of psychosocial 
interventions to draw firm conclusions concerning their efficacy (Moriyama, Polanczyk, 
Terzi, Faria, & Rohde, 2013). Furthermore, in a large multimodal randomized trial, highly 
structured psychotherapy for ADHD was compared with individual counseling. Both 
treatment approaches were combined with methylphenidate and placebo. The outcome 
measures were obtained after 12, 24, and 52 weeks, respectively. Methylphenidate was found 
to be superior to placebo and highly structured psychotherapy did not outperform individual 
counseling. One conclusion drawn was that individual counseling, which is comparable in 
efficacy with highly structured psychotherapy, may be easier to implement in practical care. 
(Philipsen et al., 2015). 
 
1.3.4 Psychological treatment of ADHD with comorbid SUD 
Whereas the body of literature on cognitive behavioral therapy (CBT) for ADHD is growing, 
studies on CBT for ADHD in combined ADHD and SUD have not yet been reported. 
Structured psychological interventions for ADHD in patients with comorbid SUD add some 
difficulties. Treatment attrition has long been identified as a problem in the treatment of 
substance dependence in general (Aharonovich et al., 2006). Amotivation (Philips & 
Wennberg, 2014) and cognitive impairments (Aharonovich et al., 2006) are also found to be 
risk factors for early discontinuation of treatments. The combination of ADHD and SUD may 
be assumed to increase the risk of treatment attrition due to impulsive action/choice, since 
impulsivity characterizes ADHD (Sonuga-Barke et al., 2008), as well as SUD (Ivanov et al., 
2008). 
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The need for alternative and complementary psychological interventions for pharmacological 
treatment of combined ADHD and SUD has, however, been highlighted more and more. An 
ongoing treatment trial of integrated cognitive behavioral therapy for patients with SUD 
along with comorbid ADHD has been presented in a study protocol (van Emmerik-van 
Oortmerssen, Vedel, et al., 2013; van Emmerik-van Oortmerssen, Vedel, van den Brink, & 
Schoevers, 2015). Multimodal treatment, including psychoeducation, coaching, and cognitive 
behavioral therapy in addition to pharmacotherapy, is also recommended in Belgium in 
practice guidelines for patients with combined ADHD and SUD (Matthys, Joostens, van den 
Brink, & Sabbe, 2013). The National Board of Health and Welfare in Sweden recommends 
concurrent interventions for combined ADHD and SUD (National Board of Health, 2014b). 
 
1.3.5 Functional long-term outcomes of ADHD-treatment 
Studies on long-term outcomes of treatments for ADHD differ in various respects: age group, 
design, treatment modalities, follow-up time, and outcome measures (Arnold, Hodgkins, 
Caci, et al., 2015; Fredriksen et al., 2012).  
In a systematic review, the functional outcome measures have been found to be partly age-
dependent (Arnold, Hodgkins, Caci, et al., 2015). Measures of academic and social function 
are most usual in childhood, and drug use and antisocial behavior in adolescence and 
adulthood. Less improvement involving pharmacological treatment has been found in 
substance use and antisocial behavior. However, a reduction of the negative impact of ADHD 
on life functioning has been found, although not to the level of healthy controls (M. Shaw et 
al., 2012), and a positive correlation between stimulant medication and employment status 
has been shown (Gjervan, Torgersen, Nordahl, & Rasmussen, 2012; Halmoy, Fasmer, 
Gillberg, & Haavik, 2009). Furthermore, prison inmates displayed improvements in 
psychosocial functioning [increased participation in educational programs and evidence-
based treatment programs, and better global functioning (GAF)] after 52 weeks of treatment 
with methylphenidate (Ginsberg et al., 2012). ADHD treatment, especially multimodal 
treatment, has also been shown to have long-term benefits for academic achievements 
(Arnold, Hodgkins, Caci, et al., 2015) 
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1.3.6 Addiction treatment 
Addiction treatment, including both pharmacological and psychosocial treatment, is beyond 
the scope of the present thesis and therefore will be summarized only briefly here. Overall 
psychosocial interventions are effective in promoting behavior changes in the addictive 
behavior (Jhanjee, 2014). The frequently used methods CBT (Carroll & Onken, 2005; 
McRae, Budney, & Brady, 2003; Weisner, Matzger, & Kaskutas, 2003), motivational 
interviewing (Smedslund et al., 2011; Vasilaki, Hosier, & Cox, 2006), and relapse prevention 
(Irvin, Bowers, Dunn, & Wang, 1999) have been found to be effective for many drugs of 
abuse. In individuals with opiate abuse, psychological treatment appears to be more effective 
when combined with substitution treatment (Jhanjee, 2014). 
 
1.3.7 The Act of compulsory care of substance abusers 
In Sweden, there is legislation within the Social Service Act pertaining to compulsory care 
for individuals with severe substance abuse, i.e. the Care of Substance Abusers (Special 
Provision) Act (Proposition 1987/88:147). The National Board of Institutional Care (Swedish 
abbreviation, SiS) is the authority responsible for all compulsory care governed by the Social 
Service Act. For application of the Compulsory Care for Substance Abuse Act, the following 
criteria must be met:  
1. There is an ongoing abuse of alcohol, drugs, or volatile solvents and the person is in 
need of care in order to break free from his substance abuse. 
2. The need for care cannot be met by voluntary measures or any other way, and 
3. Due to the substance abuse the person is: 
a. Exposing his/her psychic or mental health to severe danger 
b. Running an evident risk of ruining his/her life, or 
c. It may be feared that the person can severely harm him-/herself or a next of 
kin. 
 
Criteria 1 and 2 must be met and at least one of the points under criteria 3. 
It is the Municipal Social Ward that assesses the need for compulsory care and submits an 
application to an administrative court. According to the Act, the social services are obliged to 
apply for compulsory care if the criteria are met. 
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From the Annual Report from the National Board of Compulsory Care for 2014, it appears 
that 81% of those who have been required to undergo compulsory care after referral under the 
emergency care order did so, which means that substance abuse constituted a serious threat to 
the individuals’ mental health and/or may have even been life-threatening (National Board of 
Institutional Care, 2014). 
The stipulated treatment period of compulsory care is six months, and  includes 
detoxification, stabilization of the physical and mental state, motivational interventions, 
assessments, treatment planning, and transfer to voluntary treatment when the purpose of the 
inpatient care has been achieved (Reitan & Isaksson, 2014). However, during this period of 
six months, the SiS has the treatment responsibility, even if the treatment takes place outside 
the institution.  
1.3.7.1 Treatment planning, treatment goals, and adequate outcome measures 
The guidelines for treatment planning in the compulsory care context describe a multi-step 
process (National Board of Institutional Care, 2011). The treatment planning should inter alia 
include a mapping of the patient’s entire life situation, including assessments of the patient’s 
problems, care needs, treatment motivation, and resources. Formulations of concrete and 
realistic goals, including stepwise goals and planned efforts/activities, must be included 
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2 AIMS 
The aims of the thesis were: 
1. To conduct a clinical characterization study of men with ADHD and SUD in 
compulsory care. 
 
2.  To investigate the association between pharmacological treatment and outcome in 
men with ADHD and SUD after discharge from compulsory care. 
 
3. To evaluate the feasibility of DBT-based skills training as a voluntary intervention for 
men with ADHD and SUD in compulsory care. 
 
4. To conduct a six-month post-discharge follow-up of groups after structured skills 
training administered as a voluntary intervention in compulsory care due to SUD.  
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3 METHODS 
3.1 COMMON ELEMENTS IN THE STUDIES 
All four studies refer to individuals with ADHD and comorbid SUD in compulsory care. The 
National Board of Institutional Care (SiS) is the authority responsible for compulsory 
treatment of adults with severe substance abuse according to the Care of Substance Abusers 
(Special Provision) Act (Proposition 1987/88:147) 
3.1.1 Study setting 
In all studies, the included patients with ADHD and SUD were treated at the SiS Institution 
Hornö, Enköping, Sweden. The patient target group of the institution, which is one of 11 SiS 
institutions for SUD, is adult males who, in addition to substance abuse, are violent and/or 
may have other severe psychiatric comorbidity 
3.1.2 Diagnostic assessment 
The data in Study I-II stems from 2004–2008 and in study III-IV from 2011–2014. The 
assessment procedure was the same, including an extensive multiple data source and 
consensus-based diagnostic assessments. The diagnostic assessments were made by clinical 
psychologists and, in patients with an extensive comorbidity, the diagnosis was also 
discussed with a consulting psychiatrist. The assessment included (1) clinical interviews, (2) 
when possible, collateral information (questionnaires and clinical interviews) gathered from 
the participants’ significant others and, when available (3), additional information was 
obtained from case files from child/adolescent and/or adult psychiatry, as well as from 
institutions for involuntary care during childhood and/or adolescence, (4) standardized self-
rating questionnaires assessing childhood ADHD symptoms (WURS, Wender Utah Rating 
Scale) (Ward, Wender, & Reimherr, 1993). Neuropsychological testing was included in all 
assessments. Some assessment instruments used during 2004–2008 were replaced at the 
assessments during 2011–2014. Between 2004 and 2008, the clinical interviews were based 
on the DSM-IV (American Psychiatric Association, 1994). Between 2011 and 2014 they 
were based on a structured diagnostic interview DIVA (J. Kooij, Franken, M., 2010). The 
Brown Attention-Deficit Disorder Scales (Brown, 1996), regularly used during 2004–2008, 
were replaced by the World Health Organization Adult ADHD Self-Report Scale, ASRS 
(Kessler et al., 2005) during 2011–2014.  
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For the assessment of comorbid disorders, standardized and validated rating scales and 
interviews were used during both periods: the Structured Clinical Interview for DSM 
Disorders (SCID-I and II) (First & Herlofson, 1998a, 1998b), the Beck Depression Inventory 
(BDI) (A. T. Beck, Steer, R. A., & Brown, G. K., 2005), the Beck Anxiety Inventory (BAI) 
(A. T. Beck, Steer, R. A., 2005), and the long version of the Symptoms Checklist (SCL-90-R) 
(Degoratis, 1983).  
3.1.3 Statistical analyses 
The group comparisons were made using the Chi-square test for categorical variables and 
Student’s t-test for continuous variables. In study IV, the Fisher exact test was used due to 
small sample sizes. The degrees of freedom were corrected for unequal variance if indicated 
by Levene’s test for equality of variance. Effect sizes for t-tests were expressed as Cohen’s d 
(Cohen, 1988). Effect sizes were expressed as a ‘small’ effect from 0.2 to 0.3, a ‘medium’ 
effect around 0.5 (half a SD), and a ‘large effect’ ≥ 0.8. Effect sizes for Chi-square tests were 
expressed as Φ (Phi) and interpreted as a weak association (.10–.20), a moderate association 
(.20–.40), a relatively strong association (.40–.60), a strong association (.60–.80), or a very 
strong association (>.80).  
In study I, we investigated whether the observed differences in WAIS indexes loading on EF 
were explained by the general intellectual ability (FSIQ) using analyses of co-variance 
(ANCOVA). The EF index was entered as a dependent variable, group [ADHD/SUD versus 
ADHD/Psych (ADHD/Psychiatric outpatient group)] as a fixed factor and FSIQ as a co-
variate.  
In Study II, a multiple regression analysis was performed to adjust for the potential effect of 
follow-up time on outcome measures. Individuals for which data were missing and deceased 
individuals were excluded using pairwise exclusion from the analyses of long-term outcomes. 
The statistical analysis was performed using the SPSS statistical software package (IBM, 
SPSS, version 20). 
3.1.4 Time line for data collection 
         2008-2009             2011-2014            2012-2015 
Data collection study I, II       Data collection study III      Data collection study IV 
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3.2 STUDY I 
3.2.1 Participants 
The 60 males with ADHD and SUD in compulsory care (ADHD/SUD group) were compared 
with two other groups: 120 patients in compulsory care due to severe SUD, without a known 
ADHD diagnosis, matched for age and years of assessment (the general SUD group) and 107 
patients with ADHD without severe SUD from a psychiatric outpatient clinic (ADHD/Psych 
group). The inclusion/matching criteria in the latter comparison were sex (males), age range 
(19 to 46 years), and year of diagnostic assessment (2004–2008). 
3.2.2 Procedure 
Comparison data on the general SUD group and the ADHD/SUD group were obtained from 
an unidentified dataset from the SiS internal database (DOK, a SiS follow-up and 
documentation system). Data on the ADHD/Psych population, assessed at the 
Neuropsychiatric Unit Karolinska, Psychiatry Northwest, Stockholm, Sweden, were extracted 
from a database based on the patient’s medical records. Corresponding data in the 
ADHD/SUD group were obtained from the assessments documented in the patients’ case 
files. 
3.2.3 Measures 
In the comparison of background data between the ADHD/SUD group and the general SUD 
group, the measures were: (1) Family background (psychiatric disorder and/or substance 
abuse in one or both parents), as well as educational and vocational history; (2) Previous 
interventions and psychiatric care (educational support in primary school, possible 
compulsory care during childhood and/or adolescence, previous adult psychiatric care, 
previous imprisonment); and (3) Current clinical data (preferred abuse substance and self-
reported psychiatric symptoms). 
For the comparison between the ADHD/SUD group and the ADHD/Psych group regarding 
ADHD symptoms during childhood, the measure was the number of self-reported 
retrospective ADHD symptoms during childhood (Ward et al., 1993). In the comparison of 
the general intellectual level, the measures were Full-scale IQ (FSIQ), Verbal IQ (VIQ), 
Performance IQ (PIQ), and [WAIS-III (Weschler, 1997)]. Moreover, results on the four 
indexes were also compared: the Verbal Comprehension Index (related to Verbal IQ) and the 
Perceptual Organization Index (related to the nonverbal IQ), as well as the two indexes 
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loading on executive functions (EFs): the Working Memory Index and the Processing Speed 
Index (Weschler, 1997). 
 
3.3 STUDY II 
3.3.1 Participants 
The included participants were the same 60 adult males with ADHD and severe SUD as in 
Study I. Of the 71 patients referred for an assessment, 47 were found to have ADHD. 
Additional 13 assessed patients, who had an ADHD diagnosis prior to admission to the 
Hornö SiS Institution, were also included in the study. At the time point for follow-up, 30 
patients had received pharmacological treatment for ADHD and 30 patients had not. 
 
3.3.2 Procedure 
3.3.2.1 Rehabilitation plans 
An individualized rehabilitation plan, based on the clinical and psychosocial assessments and 
the patients’ own motivation for voluntary rehabilitation after completing compulsory care, 
was carried out for all patients. The rehabilitation options were 24-hour care in rehabilitation 
institutions, family homes, and supported housing, or outpatient care for patients having their 
own accommodation and a sufficient level of psychosocial functioning. All rehabilitation 
options included, or were combined with, psychiatric treatment and drug screening, except 
for those patients in support housing who refused parallel psychiatric treatment and/or only 
needed an accommodation. 
3.3.2.2 Pharmacological treatment 
All patients diagnosed with ADHD who were interested in starting a pharmacological 
treatment for ADHD were referred to a neuropsychiatric clinic or a clinic for addiction 
disorders in the patient’s hometown. In all referred cases, the patient’s local clinic was 
contacted in order to initiate the pharmacological treatment (to be prescribed by the local 
clinic) during the compulsory care period at the SiS Institution. Thus, the opportunities for the 
patients to receive pharmacological treatment for their ADHD depended on the local clinics’ 
routines and prerequisites.  
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3.3.2.3 Long-term follow up 
The follow-up data were collected from February, 2008, to March, 2009. The time between 
discharge from the institution and the follow-up ranged between 6 and 45 months (Md = 16 
months, M = 18. 4 months, SD = 9.79). In all cases, except for those patients who no longer 
had any contact with the social services, information was obtained from the patients´ local 
social workers. When possible, interviews with the patients were also conducted, either in 
face-to-face meetings or by phone. The questions posed to the social workers and/or the 
patients who could be reached were semi-structured. 
3.3.3 Measures 
The outcome measures were current status of substance abuse, rehabilitation status, 
accommodation, and employment. 
The current abuse status was categorized as (1) no known substance abuse, (2) no abuse due 
to compulsory care (imprisonment, forensic care, or a new period of compulsory care due to 
severe SUD), and (3) ongoing substance abuse.  
Rehabilitation status: Patients who did not require rehabilitation due to good psychosocial 
functioning were defined as having a combination of no substance abuse, independent 
accommodation (which, in some cases, included supportive housing without psychiatric 
treatment), and current employment. Voluntary rehabilitation included long-term stays at an 
abuse rehabilitation center (24-hour care), a rehabilitation-oriented family home, or 
supportive housing that included regular psychiatric care. Compulsory care was defined as 
imprisonment, forensic care, or a new period of compulsory care for substance abuse at the 
time of the follow-up assessment. No rehabilitation due to other reasons included all patients 
who did not meet the rehabilitation criteria defined above, including patients exhibiting 
ongoing drug abuse, homeless patients, and those who could not be tracked, neither through 
their social workers nor the tax authority’s population registers. However, for four of these 
patients, it was possible to obtain information from their former local social workers 
regarding some aspects of their current social situation. 
The accommodation status was categorized as (1) independent accommodation, (2) 
rehabilitation center or family home (24-hour care), (3) supported accommodation, and (4) 
compulsory care, as defined above.  
Employment status included two main categories: employed and unemployed. Employed was 
defined as all forms of structured and regular work or studies and unemployed was divided 
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into subcategories related to the causes of unemployment (compulsory care, being in 
voluntary rehabilitation, sick leave, and other reasons). 
 
3.4 STUDY III 
3.4.1 Participants 
Forty patients were included in the study on DBT-based skills training. The exclusion criteria 
were an IQ < 70, severe psychiatric comorbidity, such as psychosis, and/or suicidal behavior. 
Patients who displayed severe externalizing behavior, as well as patients who were assessed 
as not being able to attend a group treatment, were also excluded. Twenty-three patients were 
previously assessed for ADHD and 17 were assessed at the SiS Institution Hornö.  
3.4.2 Procedure 
3.4.2.1 Treatment setting 
All the participants were treated on a ward established for patients with ADHD at the SiS 
Institution Hornö. The ward staff had all been trained in the principles of DBT-based 
treatment and coaching. Every participant in the treatment program was assigned to a coach 
for daily support and for motivational interventions. One of the coaches, all of whom were 
ward staff, was always present at the treatment sessions. To encourage attendance at the 
sessions and for demonstrated treatment-related efforts, the participants received some 
modest rewards, e.g., a preferred activity with the ward staff. 
The treatment project started in September, 2011, and ended in December, 2014. Due to 
circumstances related to events at the institution, there was a couple of long breaks in the 
treatment project. 
3.4.2.2 The skills training program for ADHD 
The treatment program was based on the manual (B. Hesslinger, Philipsen, A., Richter, H., 
2010), but was adjusted somewhat in order to facilitate the reading and understanding. The 
group leaders were licensed psychologists working at SiS Institution Hornö.  
3.4.3 Measures 
3.4.3.1 Background and demographic data 
Data on the psychosocial background were obtained from the assessments documented in the 
participants’ case files and from a structured interview prior to the treatment, based on a form 
that covered both psychosocial background and present life situation. 
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3.4.3.2 Feasibility 
The criteria for good feasibility were defined as the percentage of completers (attending at ≥ 
75% of the sessions) of the treatment being 60% or more of the patients allocated to 
treatment. 
3.4.3.3 Treatment acceptability 
A Treatment Credibility Scale (TCS) (Borkovec, 1972), administrated before and after the 
treatment, was used to measure expectation for improvement and treatment credibility. In 
order to measure the participants’ confidence and satisfaction with the treatment, the patient 
evaluation form from the manual (B. Hesslinger, Philipsen, A., Richter, H., 2010) was used. 
Included items are specificity of the treatment program, increased knowledge of ADHD, 
increased ability to cope with their ADHD, experience of having opportunities to make their 
own suggestions during the sessions, and willingness to take part in a similar group in the 
future. A ranking of the most helpful treatment elements was also included. 
3.4.3.4 Efficacy-related measures 
The Current ADHD-Symptom Scale – Self Report Form (R. A. M. Barkley, K.R., , 1998) 
and a Staff Report form (modified from the Self-Reported Form for ward staff) were 
administered before and after the treatment program. The scale includes 18 symptom items 
for ADHD, corresponding to criteria for ADHD in the DSM-IV, and eight symptoms of 
externalizing behavior (such as irritability and anger outburst). The Current ADHD-Symptom 
Scale is scored from 0 to 3. To assess psychiatric symptoms, a short version of the SCL-90-R 
was used (Degoratis, 1983), scored from 0 to 4. General well-being was measured with a 
visual analog scale (VAS), ranging from 0 (worst) to 10 (best) (B. Hesslinger et al., 2002).  
 
3.5 STUDY IV 
3.5.1 Participants 
Forty patients who were included in the DBT- based skills training program, described in 
Study III, were followed up.  
3.5.2 Procedure and Measures 
Six months after discharge from compulsory care, the patients’ local social workers were 
contacted by letter with an attached short questionnaire and/or a telephone interview.  
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3.5.2.1 The DBT-based skills training 
The recruitment and treatment setting, as well as the structured skills training groups, are 
described in Study III. The Swedish version of the original German manual (B. Hesslinger, 
Philipsen, A., Richter, H., 2010) was adjusted to the patient population. Otherwise, the 
general structure of the sessions and the included themes were the same as in the manual.  
3.5.2.2 Outcome measures 
 
1. Substance abuse status [categorized as (1) no known substance abuse at the time of 
follow-up, (2) no abuse due to imprisonment, forensic care, a new period of 
compulsory care for substance abuse, or (3) ongoing substance abuse and (4) 
deceased].  
2. Rehabilitation status [categorized as (1) voluntary rehabilitation (rehabilitation center 
(24-hour care), rehabilitation-oriented family home or supportive housing in 
combination with outpatient psychiatric care and outpatient care), (2) compulsory 
care, defined as imprisonment, forensic care, or a new period of compulsory care for 
substance abuse, (3) neither voluntary rehabilitation/ treatment, nor compulsory care]. 
3.  Accommodation [categorized as (1) rehabilitation center, supported housing, (2) 
independent accommodation, and (3) no permanent housing]. 
4. Employment [categorized as (1) employed or studying, (2) on sick leave, and (3) 
neither employed, studying, nor on sick-leave].  
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4 RESULTS 
4.1 STUDY I 
In the comparison between the ADHD/SUD group (n = 60) and the general SUD group (n = 
120), it was found that both groups had an unstable family background, low educational level, 
and little work experience, as well as  no significant differences between the ADHD/SUD 
group and the general SUD group. A few statistical trends pointed towards a higher 
percentage of unstable family backgrounds in the ADHD/SUD group than in the general 
SUD group (p =.10) and towards a lower percentage of work experience in the ADHD/SUD 
than in the general SUD group (p =.10).  
Symptoms of depression and anxiety were frequently reported in both groups (85.0% in the 
ADHD/SUD group versus 84.2% in the general SUD group, n.s.), as well as self-reported 
psychotic symptoms, such as hallucinations, mainly referable to drug-induced psychotic 
symptoms or psychotic episodes (58.3% in the ADHD/SUD group and 64.2% in the general 
SUD group, n.s.). 
The ADHD/SUD group had a significantly higher degree of compulsory care during 
childhood (mostly due to substance abuse and/or antisocial behavior) compared to the general 
SUD group (p =.04). Moreover, imprisonment was significantly more frequent in the 
ADHD/SUD group than in the general SUD group (p < .001). No significant differences were 
found in previous adult psychiatric care. Data on special education in primary school was not 
available in the general SUD group. A between-group difference was found in the preferred 
abused substance (p = .05). In the ADHD/SUD group, the stimulant drugs, amphetamine and 
cocaine, were preferred in 53.3%, compared to 30.8% in the general SUD group. Alcohol and 
benzodiazepine were preferred more often in the general SUD group (21.7%, compared to 
9.0% in the ADHD/SUD group). 
In the comparison between the ADHD/SUD group and the ADHD/Psych group, it was found 
that the participants in the ADHD/SUD group reported significantly more ADHD symptoms 
in childhood as measured with WURS-25 (M = 60.15, SD = 17.25), compared to the 
ADHD/Psych group (M = 50.83, SD = 24.38) (t [120] = 3.21, p = .002, Cohen’s d = .60). 
Furthermore, the ADHD/SUD group was found to have significantly poorer results on the 
full-scale IQ test (n = 87, ADHD/Psych, and n = 51, ADHD/SUD, t [135.68] = 4.78, p < 
.001, Cohen´s d = .79). Similarly, further analyses of verbal IQ and nonverbal/performance 
IQ showed poorer results for the ADHD/SUD group: verbal IQ (n = 86, ADHD/Psych, and n 
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= 51, ADHD/SUD, t[134.58] = 4.62 , p = < .001, Cohen´s d = .77), nonverbal/performance 
IQ (n = 86, ADHD/Psych, and n = 51, ADHD/SUD, t[129.96] = 3.54 , p = .001, Cohen´s d = 
.60). Analyses of the level of the four indexes of the WAIS-III showed a similar pattern of 
results, i.e., the ADHD/SUD group performed poorer on all indexes: verbal comprehension 
index, VCI (n = 86, ADHD/Psych, and n = 51, ADHD/SUD, t[135.00] = 4.20, p < .001, 
Cohen´s d = .70); perceptual organization index, POI (n = 84, ADHD/Psych, and n = 51, 
ADHD/SUD, t[127.60] = 3.70, p < .001, Cohen`s d = .63); working memory index, WMI (n 
=  83, ADHD/Psych, and n = 51, ADHD/SUD, t[122.16] = 2.29 , p = .129, Cohen´s d = .40); 
processing speed index, PSI (n = 84, ADHD/Psych, and n = 47, ADHD/SUD, t[124.92] = 
3.50, p = .002 , Cohen´s d = .60). On controlling for FSIQ in an ANCOVA, the group 
differences in the working memory index (WMI) and speed of processing index (PSI) no 
longer reached statistical significance, indicating that there was no specific effect on EF in the 
ADHD/SUD group.  
4.2 STUDY II 
Thirty patients had received pharmacological treatment for their ADHD, while 30 had not. 
Twenty-two of those who had been treated pharmacologically at the time of follow–up had 
already started the pharmacological treatment for ADHD at the SiS Institution Hornö (with 
prescriptions from their local clinic) and eight at local out-patient clinics after discharge. 
Thirty patients had never started a pharmacological treatment for ADHD. The reasons why 
these patients never started treatment varied and are presented in Table 4. 
 
Table 4. Reasons for not receiving ADHD medication after discharge from compulsory care 
Reasons for not receiving pharmacological treatment of ADHD N of 30 
untreated 
patients 
Declined referral for stimulant medication         6 
Referral was rejected  by the local clinic (lack of psychiatrist, requirement of two years 
of sobriety, diagnosis questioned) 
        4 
 
Had not been called to an appointment with a psychiatrist after discharge         4 
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An unstable psychiatric condition         2 
Did not show up for the appointment with the psychiatrist after discharge         3 
Deceased         4 
Missing information         7 
 
No statistically significant differences between the pharmacologically treated and nontreated 
groups were found regarding growing-up conditions, IQ, educational level, work experiences, 
history of treatment interventions, or self-reported psychiatric symptoms at the time of 
assessment at SiS Institution Hornö.  
Mortality  
Five out of 60 patients (8.3%) had deceased (one in the pharmacologically treated group and 
four in the untreated group, n.s.). The mean age at death was 25.0 years (SD = 3.8).  
Substance abuse status  
Relapses into substance abuse were significantly less common in the patients in the 
pharmacologically treated ADHD group, compared to the group not treated for ADHD (p = 
.01). 
Rehabilitation status 
No rehabilitation due to good psychosocial functioning was more common in the 
pharmacologically treated group than in the untreated group (20.0% versus 10.0%). 
Voluntary treatment was more common in the pharmacologically treated group (36.7%) than 
in the untreated group (6.7%), whereas compulsory care was less frequent in the 
pharmacologically treated group (3.3%) than in the non-treated group (20.0%) (p = .01). 
Accommodation 
Twenty-one individuals in the pharmacologically treated group were staying at supporting 
housing (30.0%) or rehabilitation centers (26.7 %) according to their rehabilitation plan, 
compared to four (13.3%) in the untreated group. Nine (30.0%) of the individuals in the 
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untreated group were homeless or accommodated in compulsory care, compared to three 
(10.0%) in the treated group (p =.028).  
Employment status 
Thirty-six participants (60. %) were either in compulsory care or in voluntary rehabilitation, 
or on sick-leave. Thus, employment status was relevant for only 24 participants (15 in the 
treated group and 9 in the non-treated group). Of these 24 individuals, 20.0% in the treated 
group and 13.3 % in the untreated group had employment, while 30% in the treated group 
and 16.5% in the untreated group were unemployed (p = .028). 
 
4.3 STUDY III 
4.3.1 Feasibility 
The number of patients with ADHD estimated to meet the inclusion criteria and informed and 
requested to be included in the treatment was 70. Thirty patients declined to participate, 
signifying a refusal rate of 42.9%. 
Out of 40 patients who started the DBT-based skills training, 28 (70%) completed the 
treatment, all of whom had an attendance of at least 75% of the sessions. The mean number 
of attendances at the sessions among completers was 11.29 (SD = 1.0) (out of a maximum of 
12) and, among non-completers, 4.17 (SD = 2.0). Of the 12 non-completers, one participant 
was excluded from the treatment program by the group leaders because of severe disruptive 
behavior. Other reasons for discontinuation were “did not get anything out of the treatment” 
(n = 3), “too restless and/or difficulty to concentrate” (n=3), were transferred to a voluntary 
treatment in their community (n = 2), increasing symptoms of depression and/or anxiety (n = 
2), and absconded from the institution (n=1).  
The non-completers of the treatment program were found to have a lower educational level 
(Completers: less than 9 years, n = 4; 9 years, n = 16; Secondary school, n = 8. Non-
completers: less than 9 years, n = 8; 9 years, n = 4; Secondary school, n = 0. χ 2 = 14.5, p = 
.005), more severe ADHD symptoms during childhood (WURS 25: Completers, M = 58.27, 
SD = 11.76; Non-completers, M = 74.60, SD = 17.39, t = -3.26, p = .003), and more current 
impulsive symptoms, according to the staffs’ ratings (the Current ADHD-Symptom Scale: 
Completers M = 8.18, SD = 5.42; Non-completers M = 15.45, SD = 8.96, t = -3.11, p = .004). 
No significant differences were found regarding employment , accommodation , marital 
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status, somatic illness, current pharmacological treatment for ADHD , other psychoactive 
medication, ADHD subtype, psychiatric comorbidity [Axis I and Axis II], other 
neurodevelopment disorders, preferred abused drug , drug screening,  or full scale IQ (all p 
values > .10). 
4.3.2 Treatment acceptability 
There was a significant (p = .021) increase in the mean score on the Treatment Credibility 
Scale (TCS) from pre-intervention (M = 5.7, SD = 1.87) to post-intervention (M = 6.34, SD = 
1.89).  
According to the ratings on the patient evaluation form, the participants perceived the 
treatment as being ADHD-specific (mean score of 4.5, SD = 0.51, on a scale of 1–5). The 
lowest mean score, 3.2 (SD = 1.16), was observed for the item “Has achieved better control 
of the ADHD-related problems.” For the other three items, the average mean score was 4.0 
(SD 1.14–1.26). The patients rated the psychoeducation as the most helpful element in the 
treatment and, thereafter, the group leaders, followed by the group setting, and, lastly, the 
exercises. The participants’ mean summary evaluation of the treatment was 2.9 (SD = 0.85) 
on a scale from 1 (failed) to 4 (with honor).  
4.3.3 Efficacy related measures 
The ADHD symptoms (p < 0.001) and psychiatric symptoms (p = 0.01) were reduced from 
pre- to post-intervention in the self-ratings. General well-being increased significantly (p = < 
0.001). Contrarily, the staff reported no significant symptom reduction of ADHD symptoms 
from pre- to post-intervention.  
The self-ratings were significantly correlated with the ward staff ratings only regarding 
externalizing behavior (in both the pre-and post-intervention ratings). No significant 
correlations were found in ADHD symptoms of hyperactivity/impulsivity or inattention. 
 
4.4 STUDY IV 
Twenty-eight out of 40 patients completed the treatment while 12 patients discontinued the 
treatment.  
 40 
4.4.1 Substance abuse status 
Known relapses into substance abuse were less frequent in the completers compared to the 
noncompleters, although this difference did not reach statistical significance (p = .07). One 
patient was deceased.  
4.4.2 Rehabilitation status 
Twenty-one of the completers (21 out of 28) were in some form of voluntary treatment 
(rehabilitation centers, supporting housing including treatment, or outpatient care), while the 
corresponding figure among the non-completers was one individual (1 out of 12) (p =.001). 
The number of patients in a new treatment period in compulsory care was the same in the two 
groups (two in both groups, either in prison or compulsory care for SUD). 
4.4.3 Accommodation status 
Eleven of the completers had an accommodation in rehabilitation centers or supporting 
housing, as compared to two of the non-completers. Eight of the completers and three of the 
non-completers had their own accommodation, while six of the completers and one of the 
completers lived with a relative (partner or parent). No one was homeless among the 
completers, as compared to two of the non-completers (p = .23). 
4.4.4 Employment status 
Among the completers, ten patients had employment, eight were on sick-leave and seven had 
neither employment nor were on sick-leave. The corresponding numbers for the non-
completers were three (employment), one (on sick-leave), and four (neither employment nor 
on sick-leave). The difference between the groups was not significant (p = .26). 
4.4.5 Clinical characteristics in completers and non-completers 
The differences in clinical characteristics are described in study III. In summary, the non-
completers were found to have more dysfunctions (lower educational level and more severe 
ADHD).     
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5 DISCUSSION 
5.1 SUMMARY OF THE MAIN FINDINGS 
Compared to the general SUD group in compulsory care, the ADHD/SUD group had already 
been significantly more often in compulsory care during childhood or adolescence, as well as 
imprisoned more often as adults. The most common preferred abused substance in the 
ADHD/SUD group was stimulant drugs, while alcohol and benzodiazepine abuse was more 
common in the general SUD group. Compared to the ADHD/Psych group, the ADHD/SUD 
group reported more ADHD symptoms during childhood and performed poorer on all tests of 
general intellectual ability and executive functions.  
The pharmacologically treated and the pharmacologically untreated groups were comparable 
with regard to the demographic and background characteristics. Overall, mortality was high; 
8.3% of the participants had deceased at follow-up (one in the pharmacologically treated 
group and four in the untreated group; the between-group difference was not significant). The 
group that received pharmacological treatment for ADHD exhibited fewer substance abuse 
relapses, received more frequently voluntary treatments in accordance with a rehabilitation 
plan, required less frequent compulsory care, were more frequently accommodated in 
supportive housing or a rehabilitation center, and displayed a higher employment rate than 
the non-treated group.  
The refusal rate for the DBT-based skills training was approximately 42.9%. Of those 40 who 
started the DBT-based skills training, 28 (70%) completed the treatment (attendance at ≥ 75% 
of the sessions). The treatment acceptability was good. Both ADHD and psychiatric 
symptoms decreased from pre- to post-intervention in self-ratings, but not in staff ratings. The 
patients reported improved general well-being. The correlation between self- and staff-ratings 
was poor.  
The six-month follow-up showed that the completers were more often in voluntary 
treatments, lived in their own accommodation or rehabilitation center and had less known 
substance abuse, as compared to the non-completers. However, the groups already differed in 
certain aspects at baseline, which has to be considered in the interpretation of the results. 
 
5.2 THE COMPULSORY CARE CONTEXT 
The main purpose of the compulsory care for SUD is to interrupt an often life-threatening 
substance abuse (Proposition 1987/88:147). The local municipalities and county councils are 
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responsible for the long-term rehabilitation after completion of the compulsory care, as 
planned on the basis of the assessments during the inpatient care, and in agreement with the 
local social service and the patient. Thus, neither more prolonged structured psychotherapies 
nor pharmacological treatment for ADHD is included as regular treatment interventions. 
Prescriptions of ADHD medications must be done by the local psychiatric or addiction 
clinics, but not all local clinics agree to prescribe stimulant medication during the patients’ 
stay at the compulsory care institution.  
The included studies in the present thesis indicate, however, that both pharmacological and 
structured psychotherapies in a compulsory care context may be beneficial for this high-risk 
patient group. The compulsory care setting may have facilitated the monitoring of the 
pharmacological treatment, as well as been supportive through daily feed-back. A monitored 
and stable medication for ADHD may have also reduced the risk of relapse during the 
vulnerable period immediately after discharge. The compulsory care context for substance 
abuse has similarities with a prison context since it involves a structured environment and 
treatment monitoring. Stimulant medication in prison inmates has shown both short-term 
improvement in ADHD symptoms and long-term improvements in several functions, such 
as psychosocial functioning (Ginsberg et al., 2012; Ginsberg & Lindefors, 2012). Thus, 
starting medication at the institution may be beneficial for this therapeutically challenging 
group.  
Furthermore, the findings in Study III indicate that the DBT-based skills training program (B. 
Hesslinger, Philipsen, A., Richter, H., 2010) may be feasible in a compulsory care context. 
However, compared to an outpatient context (Hirvikoski et al., 2011), fewer patients are 
suitable for the skills training in a compulsory care context, not least due to an often low 
motivation for voluntary non-pharmacological treatments. Therefore, the feasibility criterion 
of an attrition rate of < 40% was set, as compared to <25 % in the outpatient setting. 
Compulsory care for SUD is per se an indication of low treatment motivation, since such care 
is always preceded by attempts to motivate to voluntary treatments in accordance with the 
Social Services Act. Thus, this patient group constitutes a great challenge to successful 
treatment, which has to be adapted to the patient group and the compulsory care context. 
Nevertheless, utilizing compulsory care for structured psychological treatment may be 
beneficial, since treatment programs such as DBT-based skills training are not likely be 
feasible in an outpatient context for the current patient group. 
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5.3 CLINICAL CHARATERISTICS 
5.3.1 Antisocial behavior 
A specific distinguishing characteristic, compared to a general SUD group without ADHD, 
was the early onset of antisocial behavior. The diagnostic assessments of the patients in Study 
I showed that 51.7 % in the ADHD/SUD group met the criteria for ASPD (American 
Psychiatric Association, 1994). In the assessments of the participants in Study III, the 
percentage of ASPD (American Psychiatric Association, 1994, 2013) was 55.0%, thus 
indicating that antisocial behavior is a salient characteristic in patients with ADHD and SUD 
in compulsory care. These percentages of ASPD in ADHD are in line with the findings in 
studies on treatment-seeking patients with ADHD and SUD (nearly 52.%) (van Emmerik-van 
Oortmerssen et al., 2014). Furthermore, ODD and/or CD in combination with ADHD has 
been found to be related to early onset of SUD (Z. Chang et al., 2012), as well as to a more 
severe course of SUD (August et al., 2006). However, CD during childhood and/or antisocial 
behavior without ADHD in adulthood has per se been proposed to be an independent and 
robust predictor of SUD (Couwenbergh et al., 2006; Hopfer et al., 2013; King et al., 2004; 
Rodgers et al., 2014; Saban et al., 2014; Westermeyer et al., 2005; Wilson & Levin, 2005).  
5.3.2 Additional comorbidity 
Due to the lack of established diagnoses in the general SUD group in Study I, the comparison 
with the ADHD/SUD group was based on self-reported data from comprehensive structured 
interviews documented in a database (DOK). One consequence of the self-reported data may 
be an unexpectedly high percentage of reported psychotic symptoms: 58.4% in the 
ADHD/SUD group and 64.1% in the general SUD group. However, this percentage also 
includes self-reported drug-induced psychotic symptom (such as psychotic paranoid 
symptoms related to abuse of central stimulants and hallucinations related to abuse of 
hallucinogens) or episodic psychotic symptoms, either on a single occasion or repeatedly, and 
either short-term or continuing for a longer time. In the ADHD/SUD group, 51.7% reported 
drug-induced psychotic symptoms and, in the general SUD group, the percentage was 41.0 
%. These percentages may be compared to 14.9% of reported psychotic symptoms at the 
assessments at the SiS institution Hornö, according to the assessment data. The reported 
psychotic symptoms in the patients in the skills training groups (Study III) was 8 out of 40 
(20.0%), 12.5% of which refers to psychotic episodes or drug-induced psychosis. It may be 
assumed that the percentage of psychotic symptoms reported in the assessments is more valid 
due to more thorough inquires. 
 44 
 
The rate of self-reported symptoms of depression/anxiety in Study I (85.0%) was higher than 
the rates for the established diagnosis of these disorders in Study III (77.5%). However, both 
these rates are in line with the rates of Axis I disorder over the life span in the ADHD 
population (between 65% and 89 %) (Sobanski et al., 2007; Sobanski et al., 2008) and a rate 
of more than 70.0% in patients with ADHD and SUD (Ginsberg, Hirvikoski, & Lindefors, 
2010; van Emmerik-van Oortmerssen et al., 2014). In the general SUD group, self-reported 
symptoms of depression/anxiety were also high (84.2%).  
5.3.3 Cognitive level 
An additional distinguishing characteristic of the ADHD/SUD group, compared to an 
outpatient ADHD group without severe SUD, was a poor general cognitive capacity: IQ = 87 
in Study I and IQ = 87.9 in Study III. At least two months passed between enrollment and 
completion of the detoxification and the psychological testing. It cannot be ruled out that such 
executive functions as working memory, response inhibition, processing speed, and mental 
flexibility were still affected by the severe substance abuse in some patients (Lundqvist, 
2005, 2010; Verdejo-Garcia, Bechara, Recknor, & Perez-Garcia, 2006). However, it may also 
be assumed that cognitive impairments existed before an established abuse. Special education 
support, low school performance, and a low educational level were common findings among 
the ADHD/SUD patients. However, the relationship between the cognitive status at the time 
of assessment and all possible contributing factors, such as the long-term consequences of the 
substance abuse, the premorbid cognitive level, the low educational level, and unfavourable 
growing-up conditions, is complex and impossible to determine from the data in the present 
study.  
 
5.3.4 Preferred abused substance 
A difference between the ADHD/SUD group and the general SUD group (Study I) in the 
preferred abused drug was found: considerably more patients in the general SUD group 
reported alcohol as the preferred drug (21.7% vs. 6.7%), while the ADHD/SUD group more 
often preferred stimulants. However, it is clear from the drug screening (in both Study I and 
Study III) that these patients with ADHD and SUD may be regarded as polydrug abusers and 
that the use of benzodiazepines is very common (58.3% were positive for this drug in Study I 
and 85.0% in Study III). The choice of abused drug is, however, also dependent on the 
availability of the drug, which may change from time to time.  
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5.4 TREATMENT OUTCOME 
5.4.1 Feasibility 
The results in Study III showed that the attrition rate was 30% (12 out of 40 patients 
discontinued the treatment), while the attendance at sessions was high among completers (the 
mean attendance number was 11.29 sessions out of a maximum of 12), thus indicating that 
the treatment program was feasible and acceptable for most participants. High attrition in 
psychological treatments has been demonstrated in substance dependence in general 
(Aharonovich et al., 2006). 
5.4.2 Treatment acceptability 
Treatment acceptability in Study III refers to the participants’ expectation for improvement 
and treatment credibility. Using the Treatment Credibility Scale (TCS) (Borkovec, 1972), it 
was found that the expectation for improvement/confidence in the treatment was considerably 
lower compared to what was found in a study on DBT-based skills training for ADHD in a 
psychiatric outpatient clinic (Hirvikoski et al., 2011). This applies to both the pre- and post-
ratings. This may not be surprising, given the compulsory care context and the total clinical 
burden in the current study group. However, the treatment expectancy/credibility increased 
from pre- to post-intervention, which, hopefully, may indicate an increase in the individuals’ 
propensity to participate in future psychological treatments. 
In Study II, only six patients (10%) declined referral for stimulant medication, indicating that 
that pharmacological treatment was a more accepted treatment option than DBT-based skills 
training in this patient group. 
5.4.3 Efficacy-related measures 
The finding in Study III of significant symptom reduction in all measured parameters in self-
ratings from pre-to post-intervention is in line with previous studies in psychiatric outpatient 
contexts (Hirvikoski et al., 2011; Philipsen et al., 2007). It may be assumed that the symptom 
reduction is not only attributable to the treatment program, but also to general/nonspecific 
therapeutic factors (Strupp, 1986). Furthermore, the staff ratings did not indicate a reduction 
of ADHD symptoms and the correlations between self- and staff ratings was poor. The scores 
on self-rated ADHD symptoms (M = 32.7) were, however, comparable with the scores in the 
psychiatric outpatient ADHD group (M = 28.0), using the same rating scale (Hirvikoski et al., 
2011). The lack of a control group complicates the interpretation of the relatively low mean 
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score (M = 17.82) in the ward staff’s ratings, as well as the interpretation of the reduction of 
symptoms.  
5.4.4 Long-term outcome measures 
Long-term functional goals for chronic conditions with a complex symptomatology,  such as 
ADHD, may be expressed in terms of functional remission/recuperation and freedom from 
additional impairments (Rostain, Jensen, Connor, Miesle, & Faraone, 2013). Concrete and 
realistic goals are recommended for treatment planning in the clinical guidelines (National 
Board of Institutional Care, 2011). The functional long-term outcome measures in Studies II 
and IV, Current abuse status, Rehabilitation status, Accommodation status, and Employment 
status, are in line with these standpoints and may be regarded as relevant, given the patient 
characteristics and the clinical context. Furthermore, mortality is a relevant outcome measure, 
given the high mortality in this patient group.  
In both Study II and Study IV, the aims were to explore the association between a specific 
treatment modality (pharmacological treatment in Study II and DBT-based skills training in 
Study IV) and the psychosocial outcome after discharge. However, the studies differed in 
several aspects, e.g., the follow-up periods were different, which may have affected the 
rehabilitation status at the time of the follow-up. The mortality rate may also be assumed to 
be lower in the six-month follow-up than after a mean follow-up time of just over 18 months.  
In individuals with ADHD and SUD, pharmacological treatment of ADHD has exerted a 
moderate or negligible effect on ADHD symptoms. However, the effect of pharmacotherapy 
on substance abuse is uncertain (Castells et al., 2011; Cunill et al., 2014; T. E. Wilens, 
Monuteaux, et al., 2005). Long-term studies on pharmacological treatment for ADHD in 
patients with combined ADHD and SUD are scare. In a retrospective naturalistic study of 
adults with ADHD, comorbid SUD has been found to increase the risk of discontinuation of 
the stimulant medication (Torgersen, Gjervan, Nordahl, & Rasmussen, 2012). However, on 
controlling for SUD (in a prison context), methylphenidate (MPH) was shown to reduce 
ADHD symptoms and improve global functioning, quality of life, and cognitive functions in 
adult male long-term inmates (Ginsberg et al., 2012). Study II also indicates that 
pharmacological treatment for ADHD may improve long-term psychosocial functioning. In 
all measured parameters, the psychosocial outcome was better in the pharmacologically 
treated group than in the untreated group. Furthermore, symptom reduction and decreased 
risks for relapses have been found in two recent trials in which higher doses have been 
administered to individuals with ADHD and SUD: (1) individualized treatment protocols up 
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to 180 mg/day with methylphenidate (Konstenius et al., 2013) and (2) treatment with 
extended-release mixed amphetamine salts (60 or 80 mg) in combination with cognitive 
behavior therapy (Levin et al., 2015).   
The six-month follow-up in Study IV showed that the psychosocial outcomes were better in 
the completers than in the non-completers. It is not possible, however, to draw any firm 
conclusions as to whether the better outcomes were related to the skills training program, 
given that the completer versus non-completer groups differed in certain aspects at baseline. 
However, one conclusion is that it is important to consider the severely disabled patients’ 
ability to benefit from the treatment since discontinuation may be experienced as an 
additional failure. An individualized treatment may be needed for the patients at risk for 
treatment discontinuation.  
5.4.5 Mortality 
Individuals with ADHD have a higher mortality rate than individuals without ADHD 
(Dalsgaard et al., 2015). In combination with SUD, ODD and CD, the mortality rate increases 
(ibid.). The mortality in individuals with substance abuse is also high (Fugelstad, Annell, & 
Agren, 2014; Nyhlen, Fridell, Backstrom, Hesse, & Krantz, 2011; Stenbacka et al., 2010). 
Among individuals treated in compulsory care for severe SUD between 1999 and 2003, 5.3% 
had died (6.0% of male patients) within 12 months after discharge from compulsory care. (J. 
Larsson, & Leiniö, T. L., 2012). A register study of individuals treated in Swedish 
compulsory care between 2001 and 2009 demonstrated eight-fold mortality compared to the 
general Swedish population (Hall et al., 2015). The mortality rate for all patients in Study II, 
with a mean follow-up time of 18 months, was 8.3%. Thus, the mortality in patients with 
ADHD and SUD in compulsory care must be regarded as very high. In the six-month follow-
up study (Study IV), mortality was not treated as a general outcome measure due to the short 
follow-up time. Instead, ‘Deceased’ was included as a category within the substance abuse 
status. One person had deceased during the six-month follow-up period (2.5%).  
 
5.5 LIMITATIONS 
A limitation in Study I is that the number of undiagnosed ADHD patients in the general SUD 
group was unknown. Bearing in mind the high prevalence of ADHD in substance abusers 
(van Emmerik-van Oortmerssen, Vedel, et al., 2013), it may be assumed that some 
individuals in the general SUD group had an undiagnosed ADHD. The differences between 
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the ADHD/SUD group and the general SUD group may have been larger if undiagnosed 
ADHD in the general SUD group could have been entirely ruled out.  
The proportion of missing data was relatively high in the pharmacologically nontreated group 
in Study II. However, in accordance with clinical experience and anecdotal information from 
their social workers, these patients were assumed to have relapsed into substance abuse. 
Thus, the differences between the pharmacologically treated group and the non-treated group 
would be even greater if this assumption is correct.  
The generalizability of the results in all studies included in the present thesis may be limited 
due to the extensive clinical burden in the patient group. Thus, the results may not 
characterize the total population of individuals with ADHD and comorbid SUD. The 
generalizability may also be limited by the study context of compulsory care. However, 
individuals who exhibit a high symptom severity of both ADHD and SUD, in addition to 
other comorbid psychiatric disorders, are often met in other compulsory care settings, such as 
forensic care and institutional youth care, and also in voluntary outpatient and inpatient 
addiction and psychiatric clinics (Klein et al., 1997; Rosler et al., 2004; Torok et al., 2012).  
The lack of a control group is the major limitation in Study III. The primary aim was, 
however, to evaluate whether the treatment program was at all feasible, given the compulsory 
treatment context, the severely impaired patient group, and the resource allocation demands 
that the treatment program made on the SiS Institution. In study IV, it was not possible to 
draw any causal conclusion concerning the relationship between the DBT-based skills 
training and the psychosocial outcome due to the baseline differences between completers 
and non-completers, as well as the lack of a control group. 
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6  CONCLUSIONS 
A conclusion drawn from Study I is that ADHD in combination with SUD is a particularly 
disabling condition, comprising poor general cognitive ability, severe psychosocial problems 
(including early and persistent antisocial behavior) and other co-existing psychiatric 
conditions. These findings suggest that undiagnosed ADHD with comorbid SUD constitutes 
a high risk for the development of an extensive clinical burden. This burden is, in turn, 
associated with high risk behaviors, including increased risks for accidents, criminality, drug 
overdoses, and mortality, as well as family burdens and high societal costs.  
The long-term follow-up study showed that only 30 (out of 60) patients were medicated for 
ADHD, which indicates that the availability of pharmacological treatment was poor. This 
may be regarded as especially worrisome, given the severity of the clinical impairment in the 
group and the indication of treatment benefits with regard to the psychosocial outcome. 
It is a challenging task for clinicians to balance the pharmacological needs of the patients 
with ADHD and severe SUD with the risk of drug misuse and diversion. The compulsory 
care context may facilitate the initiation of pharmacological treatment through the structured 
treatment setting, including monitoring to prevent misuse or diversion of the medication. 
Furthermore, initiating the pharmacological treatment at the compulsory care institution may 
have reduced the risk of relapse during the vulnerable period immediately after discharge. 
Pharmacological treatment appears to be a more preferable treatment modality than 
structured psychotherapy in ADHD/SUD patients. However, the DBT-based skills training 
program for ADHD was also feasible and acceptable and may have contributed to symptom 
reduction in some patients in compulsory care. Discontinuation of a voluntary treatment 
program in a compulsory care context may be an adverse prognostic sign in this patient 
group.   
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7 FURURE DIRECTIONS 
The studies in the present thesis refer to the population of men with ADHD in compulsory 
care for SUD. However, women with ADHD and SUD in compulsory care have not been 
clinically characterized. Moreover, studies that evaluate the long-term psychosocial outcomes 
of pharmacological treatment for ADHD have not been conducted on women with ADHD 
and severe SUD after discharge from compulsory care. Therefore, studies including both 
women and men are necessary to further characterize individuals with ADHD in compulsory 
care due to SUD. Likewise, treatment studies including both men and women with ADHD in 
compulsory care due to SUD are desirable.  
For patients with combined ADHD and SUD, additional efforts are needed to develop 
treatment strategies that both meet the patients’ need for adequate pharmacological treatment 
and reduce such risks as misuse and diversion. (Bukstein, 2008; Kollins, 2008; Mariani & 
Levin, 2007; Upadhyaya, 2007). Future studies on these topics may be helpful for clinicians 
in their dilemma concerning treatment of this patient group. The trials with individualized 
treatment protocols in incarcerated men with ADHD and SUD (Konstenius et al., 2013) and 
with extended-release mixed amphetamine salts in combination with cognitive behavior 
therapy in patients with ADHD and cocaine use disorder (Levin et al., 2015) are encouraging 
since they have demonstrated both fewer relapses in substance use and ADHD symptom 
reduction.  
More studies on psychological treatment programs adapted to the clinical characteristics of 
patients with ADHD and SUD are needed. Replications of studies on programs also targeting 
the antisocial behavior, such as the Reasoning and Rehabilitation ADHD Program (Emilsson 
et al., 2011; Young et al., 2013), would be valuable for patients with ADHD in compulsory 
care due to SUD. 
Both ADHD and substance abuse are independently associated with an increased risk for 
mortality (Barbaresi et al., 2013; Dalsgaard et al., 2015; Fridell & Hesse, 2006; Johnson, 
Finney, & Moos, 2005; Nyhlen et al., 2011). Study II demonstrated a very high mortality in 
patients with ADHD who had been treated in compulsory care for SUD. A more 
comprehensive mortality study that compares ADHD/SUD patients in compulsory care with 
general SUD patients without ADHD would increase our knowledge of the risks in this 
patient group.  
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